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Acquire biopotential data from a region of 
tissue to be stimulated 
Perform a computational analysis of the 
acquired biopotential data 
Identify and place sufficient leads to provide a 
number of possible conduction paths passing 
in close proximity to the region of tissue of 
interest 
Dynamically control electrical signal delivery 
to the region of tissue of interest by selectively 
switching the use of the leads as conductors 
and grounds 
Vary stimulation intensity through one or more 
external stimulation devices, including an 
optical stimulation device, an electromagnetic 
field-producing device, an electromechanical 
stimulation device, and an audio stimulation 
device. 
Assess acquired data for the purpose of 
subsequent altering of lead use 
End 
Fig. 20 
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Acquire biopotential voltage data from a 
region of tissue to be stimulated 
Use biopotential voltage data to determine 
parametric values of an electrical tissue 
stimulation signal 
Generate and apply to the region an electrical 
stimulation signal with the determined 
parametric values 
Control signal application time by responding 
to one or more parameters established through 
analysis of empirical data, tissue electrical 
properties, brain tissue EEG data, tissue 
impedance, oxygen saturation, EMG activity, 
electrocardiographic activity, biochemical 
levels, respiration patterns, and/or an 
arbitrarily set maximum time limit. 
Fig. 21 
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Measure the electrical properties of a region of 
tissue to be stimulated 
Compare the measurements statistically with 
measures known to represent normal tissue 
electrical properties in a normal healthy 
population of living beings 
Use data from the comparisons to determine 
parametric values of an electrical tissue 
stimulation signal 
Generate and apply to the region an electrical 
stimulation signal with the determined 
parametric values 
Fig. 22 
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Measure biochemicals in tissues and fluids 
relevant to the region to be stimulated 
Analyze the measurements and determine 
parametric values of an electrical tissue 
stimulation signal in accordance with the 
analysis. 
Generate and apply to the region an electrical 
stimulation signal configured to reduce tissue 
impedance and increase depth of signal 
penetration with the determined parametric 
values 
Fig. 23 
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Place at least one stimulating lead in proximity 
to each desired region of tissue 
Place at least one ground lead in proximity to 
each selected tissue region such that a vector 
path extends between each stimulating lead 
and each ground lead that passes through each 
selected tissue region 
Introduce an electrical stimulation signal 
through at least one stimulating lead such that 
current is caused to flow along the vector 
path(s) 
Using a stimulation switching circuit and 
ground switching circuit coupled to a plurality 
of leads, selectively cause the leads to serve as 
either stimulation or ground leads in such a 
way as to create multiple spatial paths of 
electrical stimulation through tissues 
Fig. 24 
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Measure the electrical properties of a subject 
Transmit the measurements to a remote 
location over a network 
Analyze the measurements at the remote 
location 
Remotely determine parametric values for an 
electrical tissue signal in response to the 
analysis 
Transmit the parametric values over a network 
to an electrical stimulation apparatus 
Cause the electrical stimulation apparatus to 
generate and apply an electrical stimulation 
signal having the remotely determined 
parametric values 
Fig. 25 
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Measure biophysical activity such as but not limited to EEG 
and EMG in a portion of the body to be treated. (S1) 
Compare the measured biophysical activity to normal 
biophysical activity for that portion of the body. (S2) 
Determine the site to which electrical stimulation will be 
applied based on regions where the measured biophysical 
activity differ from the normal biophysical activity. (S3) 
Determine the stimulating signal's electrical parameters based 
on the comparison of the measured biophysical activity to the 
normal biophysical activity. (S4) 
Place at least one stimulating lead in proximity to the 
determined site. (S5) 
Place at least one ground lead to create a vector between the 
stimulating lead and the ground lead that passes through the 
determined site. (S6) 
Apply an electrical signal through the leads with the determined 
electrical parameters. (S7) 
Acquire information from a sensory input to quantify the 
condition of the site being treated or the functional state of the 
subject being treated, relatively concurrent with the application 
of the electrical signal. (S8) 
Alter at least one parameter of the electrical signal based on a 
comparison of the information acquired from the sensory input 
and a desired value in a normal subject. (S9) 
End 
Fig. 26 
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1. 
METHODS AND APPARATUS FOR 
ELECTRICAL STIMULATION OF TSSUES 
USING SIGNALS THAT MINIMIZE THE 
EFFECTS OF TISSUE IMPEDANCE 
CROSS-REFERENCES TO RELATED 
APPLICATIONS 
This application is a Continuation-in-Part of U.S. patent 
application Ser. No. 1 1/490,255 which is a continuation of 
U.S. patent application Ser. No. 10/357,503 which claims 
priority in an earlier filed provisional application U.S. Ser. 
No. 60/353,234, filed on Feb. 4, 2002; this application also 
claims priority in and incorporates by reference U.S. Provi 
sional Patent Application Ser. No. 60/963,486 filed 6 Aug. 
2007, U.S. Provisional Patent Application Ser. No. 61/014, 
917 filed 19 Dec. 2007, and U.S. Provisional Patent Applica 
tion Ser. No. 61/024,641 filed 30 Jan. 2008, and U.S. Provi 
sional Patent Application Ser. No. 61/032,241 filed 28 Feb. 
2008. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the field of pro 
ducing and applying electrical energy to tissues for the pur 
pose of stimulating Such tissues, and to therapeutic methods 
and apparatus. More specifically, the present invention relates 
to a system for providing and using electrical signals having 
characteristics that allow them to minimize electrical imped 
ance of tissues, and more specifically yet, to various methods 
and apparatus for providing Such signals for the purpose of 
providing therapeutic benefit to a living being. 
2. Description of Related Art 
A number of examples of recent patents may be used to 
understand the background of the present invention, as well as 
Some of the limitations it overcomes. For example, Boveja, et 
al. in U.S. Pat. No. 7,076.307 disclose a method for pulsed 
electrical stimulation of the vagus nerve as a means of pro 
viding therapy for a number of neurological disorders. As 
another example, Whitehurst, et al., disclose in several pat 
ents (U.S. Pat. No. 7,013,177; U.S. Pat. No. 6,950,707; U.S. 
Pat. No. 6,922,590; U.S. Pat. No. 6,901,294; and U.S. Pat. 
No. 6,871,099) methods for treating a number of disorders 
involving the application of electrical stimulation to the brain 
and/or the spinal cord. In these patents, the method of delivery 
for the electrical stimulation signal involves Surgically 
implanting some device within the tissues. The disclosure of 
King in U.S. Pat. No. 6,745,079 is yet another example of 
teachings involving implantation for electrical stimulation. 
However, King teaches the use of implantable electrodes 
associated with an external device. 
More general examples of patents exist that describe the 
benefit of electrical stimulation of tissues. These examples 
include the teachings of Carter (U.S. Pat. No. 6,853,863) and 
Borkan (U.S. Pat. No. 6,662,053). In U.S. Pat. No. 7,054,686, 
MacDonald discloses a process for stimulating tissue, such as 
cardiac tissue, nerve tissue, and brain tissue, by delivering a 
sequence of individual pulses. George, et al., disclose in U.S. 
Pat. No. 7.024.239 a method ofusing electromagnetic energy 
as a form of tissue stimulation for the purposes of treating 
chronic wounds. Similar teachings exist for the use of elec 
trical stimulation in speeding the healing process of wounds, 
and in particular, to the repair process of injured bones (U.S. 
Pat. No. 6,858,000 by Schukin, et al. and U.S. Pat. No. 6,678, 
562 by Tepper, et al.). 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
Among other things, none of these patents discloses any 
consideration of the electrical nature of the tissues them 
selves, either at the macro level or at the basic cellular level, 
or of how tissue stimulation signals might be adapted to take 
into account that electrical nature. At the macro level, a reduc 
tion of the fundamental impedance of tissues will have the 
effect of providing for increased conductance and hence 
deeper penetration of an applied electrical signal or field into 
said tissues. At the cellular level, impedance changes simi 
larly affect conductance, and also in the case of neural cells, 
probably affect electrical properties such as nerve conduction 
Velocity and neuron firing rates. As with all materials that 
have the ability to conduct electricity, the impedance of tis 
Sues involves components of both resistance and reactance. 
Generally speaking, tissue is a relatively poor conductor of 
electricity due to high resistance values. However, tissues 
also have a capacitive nature that provides for a form of 
impedance formally known as capacitive reactance. 
Capacitive reactance decreases as the frequency of an elec 
trical signal increases. This principle is the basis for the gen 
eral knowledge that an ideal capacitor will completely block 
a Zero-frequency signal (also known as a “DC signal) since 
the capacitor's capacitive reactance will be infinite. Similarly, 
the same capacitor will pose very little impedance to a signal 
of very high frequency. Considering the capacitive nature of 
tissues, higher frequency signals are more readily conducted 
through them. 
However, for the purposes of affecting tissues in a thera 
peutic way, lower frequency signals are relevant. Thus, a 
paradox exists in the pursuit of the use of electricity for 
therapeutic purposes in that, while the low frequency signals 
are useful for affecting tissues and biochemicals, they are also 
most severely attenuated by tissue impedance. 
The patents discussed above generally attempt to over 
come this by using implantable devices that place the source 
of the electrical stimulating energy in close proximity to the 
tissues meant to be stimulated, or by providing stimulating 
electricity at levels that are sufficiently high to allow for 
attenuation and still accomplish an effect. In the latter case, 
the comfort of the subject receiving the stimulation electricity 
is frequently compromised during therapy. 
SUMMARY OF THE INVENTION 
A tissue stimulation apparatus is provided comprising an 
electrical stimulation device 1 that includes a stimulation 
signal generation circuit configured to generate an electrical 
tissue stimulation signal that reduces tissue impedance and 
increases depth of signal penetration. 
Also, a tissue stimulation method is provided, which com 
prises the steps of providing a tissue stimulation apparatus 
configured to dynamically alter the use of leads between 
conducting biopotential Voltages, conducting an electrical 
signal for stimulating tissues, and grounding, in response to a 
computational analysis of biopotential data acquired from a 
region of tissue to be stimulated; acquiring biopotential data 
from a region of tissue to be stimulated; performing a com 
putational analysis of the acquired biopotential data; in 
response to the analysis, identifying and placing Sufficient 
leads so as to provide a number of possible conduction paths 
passing in near proximity to a region of tissue of interest; and 
dynamically controlling electrical signal delivery to the 
region of tissue of interest by selectively switching the use of 
the leads as conductors and grounds. 
A further tissue stimulation method is provided, which 
includes the steps of determining parametric values of an 
electrical tissue stimulation signal by obtaining biopotential 
US 8,494,625 B2 
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Voltage data from a region of tissue to be stimulated, and 
determining parametric values of an electrical tissue stimu 
lation signal in response to the biopotential Voltage data; and 
generating and applying to the region of tissue an electrical 
stimulation signal having the determined parametric values. 
Another tissue stimulation method is provided, which 
includes the steps of determining parametric values of an 
electrical tissue stimulation signal by taking measures of 
electrical properties of a region of tissue to be stimulated, 
making statistical comparisons between the measures and 
measures known to represent normal tissue electrical proper 
ties in a healthy normal population of living beings, deter 
mining parametric values of an electrical tissue stimulation 
signal in response to the comparisons, and generating and 
applying to the region of tissue an electrical stimulation signal 
having the determined parametric values. 
Another tissue stimulation method is provided, which 
includes the steps of determining parametric values of an 
electrical tissue stimulation signal by taking measures of 
biochemicals from tissues and/or fluids relevant to the tissues 
to be stimulated, analyzing the measures, and determining 
parametric values of an electrical tissue stimulation signal in 
accordance with the analysis of the measures. An electrical 
stimulation signal having the determined parametric values 
and configured to reduce tissue impedance and increase depth 
of signal penetration is generated and applied to the region of 
tissue. 
Also provided is a method of directing electrical stimula 
tion signals through desired tissue regions. This method 
includes the steps of placing at least one stimulating lead 21 in 
proximity to the or each desired tissue region, placing at least 
one ground lead 20 in another proximity to the or each desired 
tissue region Such that a vector path extends between the or 
each stimulating lead and the or each ground lead and passes 
through the or each desired tissue region, and introducing an 
electrical stimulation signal through the at least one stimulat 
ing lead such that current is caused to flow along the or each 
vector path through the or each tissue region between the or 
each stimulating lead and the or each ground lead. 
Also provided is a tissue stimulation method that includes 
the steps of determining parametric values of an electrical 
tissue stimulation signal by taking measures of electrical 
properties of a Subject, transmitting the measures to a remote 
location via a network, analyzing the measures at the remote 
location, remotely determining parametric values of an elec 
trical tissue stimulation signal in response to the analysis, 
transmitting the parametric values from the remote location 
via a network to an electrical stimulation apparatus, and caus 
ing the electrical stimulation apparatus to generate and apply 
to the region of tissue an electrical stimulation signal having 
the remotely determined parametric values. 
Also provided is a method for treatment of conditions using 
electrical tissue stimulation signals, which includes the steps 
of measuring biophysical activity in a portion of a subjects 
body to be treated, analyzing the measured biophysical activ 
ity, determining the or each site to which electrical stimula 
tion will be applied, determining electrical parameters for the 
electrical signal to be applied to the subject, which will tend 
to bring the subject’s biophysical values for the determined 
site to more normal, desired values, placing at least one stimu 
lating lead in proximity to the or each determined site, placing 
the or each ground lead so as to create a vector direction 
between the or each stimulating lead and the or each ground 
lead that will cause at least one path of electrical stimulation 
to pass through the or each determined site, and applying 
through the leads an electrical signal having the determined 
parameters. 
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Also provided is a method for treating conditions associ 
ated with central nervous system dysfunction. This method 
includes applying an electrical tissue stimulation signal to a 
Subject Suffering from one or more conditions selected from 
the group of conditions consisting offibromyalgia syndrome, 
chronic pain, traumatic brain injury, affective disorders. Such 
as attention deficit disorder (ADD) and attention deficit 
hyperactivity disorder (ADHD), chronic fatigue, sleep disor 
ders, obsessive compulsive disorder, Tourette Syndrome, 
depression, anxiety, and addiction. 
Also provided is a method for treating conditions associ 
ated with abnormal levels of biochemicals in tissues. This 
method includes applying an electrical tissue stimulation sig 
nal to a Subject Suffering from one or more conditions 
selected from the group of conditions consisting of fibromy 
algia syndrome, chronic fatigue, obesity, chronic pain, 
muscle pain, myofascial pain, myofascial trigger points, and 
psychological conditions, such as depression. 
Also provided is a method for enhancing a body's own 
healing mechanisms. This method includes applying an elec 
trical tissue stimulation signal to a subject Suffering from one 
or more conditions selected from the group of conditions 
consisting of broken bones, injured tissues, post-Surgical 
wounds, cuts, muscle pain associated with strains, and 
Spasms. 
Also provided is a method for improving a body's function. 
This method includes applying an electrical tissue stimula 
tion signal to a Subject, the signal configured and applied in 
Sucha way as to produce one or more effects selected from the 
group of effects consisting of reducing fatigue, increasing 
alertness, and increasing mental clarity. 
Also provided is a method for enhancing performance 
measures of a subject. This method includes applying an 
electrical stimulation signal to a subject, the signal configured 
and applied in Such a way as to enhance performance mea 
Sures associated with one or more endeavors selected from 
the group of endeavors consisting of athletic and academic 
endeavors. 
Also provided is a method for enhancing organ function in 
a Subject. This method includes applying an electrical stimu 
lation signal to a Subject, the signal configured and applied in 
Such a way as to advantageously enhancing the function of an 
Organ. 
Additional advantages and novel features of the invention 
will be set forth in part in the description that follows, and in 
part will become more apparent to those skilled in the art upon 
examination of the following or upon learning by practice of 
the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the present inven 
tion, the needs satisfied thereby, and the features, and advan 
tages thereof, reference now is made to the following descrip 
tion taken in connection with the accompanying drawings. 
FIG. 1 shows an apparatus constructed according to the 
invention; 
FIG. 2 shows a graphic representation of the neurostimu 
lation signal; 
FIG.3 shows a model of the apparatus of FIG. 1 in regards 
to tissue impedance; 
FIG. 4 shows another view of the apparatus of FIG. 1; 
FIG. 5 shows a diagram of a high frequency signal, for use 
in accordance with an embodiment of the present invention. 
FIG. 6 shows a diagram of a low frequency signal, for use 
in accordance with an embodiment of the present invention. 
US 8,494,625 B2 
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FIG. 7 shows a diagram of an amplitude modulated pulse 
width modulated signal, for use in accordance with an 
embodiment of the present invention. 
FIG. 8 shows a diagram of a low frequency sinusoidal 
signal, for use in accordance with an embodiment of the 
present invention. 
FIG. 9 shows a diagram of a sinusoidal amplitude modu 
lated pulse width modulated signal, for use in accordance 
with an embodiment of the present invention. 
FIG. 10 shows a diagram of a low frequency composite 
sinusoidal signal, for use in accordance with an embodiment 
of the present invention. 
FIG. 11 shows a diagram of a composite sinusoidal ampli 
tude modulated pulse width modulated signal, for use in 
accordance with an embodiment of the present invention. 
FIG. 12 shows a diagram of an electrical stimulation appa 
ratus, in accordance with an embodiment of the present inven 
tion. 
FIG. 13 shows a diagram of an electrical stimulation appa 
ratus, in accordance with an embodiment of the present inven 
tion; 
FIG. 14 shows a diagram of an electrical stimulation appa 
ratus, in accordance with an embodiment of the present inven 
tion; 
FIG. 15 shows a diagram of an electrical stimulation appa 
ratus, in accordance with an embodiment of the present inven 
tion; 
FIG. 16 shows a diagram of a Switching circuit, in accor 
dance with an embodiment of the present invention; 
FIG. 17 shows a diagram of an electrical stimulation appa 
ratus, in accordance with an embodiment of the present inven 
tion; 
FIG. 18 shows a diagram of an electrical stimulation appa 
ratus, in accordance with an embodiment of the present inven 
tion; 
FIG. 19 shows a diagram of a mobile electrical stimulation 
apparatus, in accordance with an embodiment of the present 
invention; 
FIG. 20 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 21 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 22 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 23 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 24 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 25 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 26 shows a flow diagram of method of applying 
therapeutic electrical stimulation, in accordance with an 
embodiment of the present invention; 
FIG. 27 shows a diagram of a computer system, in accor 
dance with an embodiment of the present invention. 
DETAILED DESCRIPTION 
The present invention is directed towards a method and an 
apparatus Suitable for the treatment of neurological dysfunc 
tions. 
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The term “optical unit is intended to define an apparatus 
that is used on or in close proximity to the eyes. By close 
proximity, it is meanta distance from the eyes of a Subject that 
is effective for the transmittal of a light pulse into the eyes of 
the subject. Preferably, close proximity will not exceed one 
foot in distance from the subject. The structure of the optical 
unit may be worn on the face of the patient, such as optical 
device or goggles, or it may be located in a separate structure, 
Such as a stand that is held near the face or even a hand-held 
mask. Further, the optic unit may be placed at an angle to the 
eyes of the Subject. Additionally, the optic unit may be posi 
tioned behind the subject and use mirrors or other reflective 
devices (such as a white wall) to reflect the light pulse into the 
eyes of the subject. However, in no way is this definition 
intended to limit the ultimate structure the optical unit may 
take. 
The term “neurological dysfunction' is intended to define 
a group of disorders in which one or more regions of a Sub ject's brain operate at frequencies which are different from 
the predetermined frequency for that region of the brain or 
from the predetermined frequencies of the other regions of the 
Subject's brain. Examples of neurological dysfunctions 
include traumatic brain injury, post traumatic stress disorder, 
post stroke paralysis, post traumatic brain injury paralysis, 
cerebral palsy, headache, depression, post chemotherapy 
cognitive, mood and fatigue disorder, fibromyalgia, memory 
loss, coma, attention deficit disorder, etc. However, the 
present invention is not to be construed as being limited to the 
treatment of these listed examples. 
The term “irregular activity” is intended to define the EEG 
frequency of an region of the Subject’s brain which does not 
match the predetermined EEG activity of the remaining 
regions of the subjects brain. Additionally, the term “irregu 
laractivity” is also intended to define an EEG frequency of an 
region of the subject's brain that matches the EEG activity of 
the remaining regions of the Subject's brain, but with a high 
degree of variance. Irregular activity is determined by ana 
lyzing the frequency bands of the region of the brain being 
investigated and identifying either a higher band amplitude or 
a lower band amplitude than is predetermined for that region. 
Examples of potential irregular activity include amplitude 
abnormalities in which the measured peak-to-peak micro 
volts is over 14 microvolts (abnormally high) or in which the 
measured microvolts is under 5 Volts from peak-to-peak (ab 
normally low) or possesses a standard deviation of over 3 
microvolts. However, these are examples only. One of ordi 
nary skill would recognize what a proper benchmark would 
be for each subject. 
The term “neurostimulation signal' is intended to define a 
signal transmitted by the neurostimulator to a subject for the 
purpose of normalizing the brainwave activity of regions of 
the Subject's brain that possess irregular activity. The neuro 
stimulation signal is determined on a subject by Subject basis 
and is changed in relation to a shift in the region's dominant 
frequency. There is typically a reduction in variability as EEG 
changes occur. This is evidenced by a shift in the dominant 
frequency more towards the typical frequencies and ampli 
tudes that were predetermined for that region of the subjects 
brain. 
The term “normalization' is intended to define the result of 
the administration of a neurostimulation signal to regions of 
the subjects brain that correspond to the regions of the sub ject's brain that possess irregular activity. The neurostimula 
tion signal is intended to “normalize' or adjust the brainwave 
frequency of the regions of the Subject's brain that possess 
irregular activity to reflect the predetermined frequency of the 
region of the subject's brain that is being treated. 
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The term “dominant frequency’ is intended to define the 
frequency in the EEG measurements taken from an area of the 
Subject’s brain that possesses the highest Voltage amplitude. 
The present invention is directed towards the alleviation of 
symptoms of neurological disorders caused by irregular EEG 
activity in a subject’s brain. The alleviation of the symptoms 
is accomplished by administering a neurostimulation signal 
to the regions of the subject’s brain that are related to those 
regions of the Subject's brain that possess irregular activity. 
These related regions of the subject’s brain can include 
regions that possess irregular activity, or other regions of the 
brain. One of skill in the neurological arts would recognize 
which regions of the brain are interrelated with other regions 
of the brain. 
For example, in one method of choosing the treatment 
sites, the choice is determined by the regions of EEG-slowing 
specific to an individual, regardless of the diagnosis. In this 
method, it is the presence and pattern of EEG-slowing at any 
of the standard neurological 10-20 sites (as selected by the 
International 10-20 EEG Site Placement Standard) that is the 
indication of the appropriateness of an region of the brain for 
treatment. The EEG-slowing pattern also determines where 
on the scalp electrodes will be placed for treatment. 
Because EEG slowing that is associated with fatigue, poor 
short-term memory, and attention problems is likely to 
involve functional deficits in the left frontal lobes of the 
brains, placing electrodes on any of the following sites is a 
reasonable directive: FP1, F7, F3, C3, F1, AF7, F5, AF3 and 
possibly temporal sites, T3 & T5 (according to the Interna 
tional 10-20 EEG Site Placement Standard). The amplitudes 
and standard deviations from the image data determine the 
order of treatment for these sites. 
The imaging data is preferably gathered by sequentially 
recording from each of 21 sites. These data are preferably 
processed through a Fast Fourier Transform (FFT) computa 
tion which produces quantitative data that shows the average 
microvolts and the standard deviation for each frequency 
component of the EEG signal at each site. A preferred method 
of treatment is to identify those sites that have the highest 
standard deviation as shown in the FFT results and treat them 
first. Treatment can be accomplished by placing two pairs of 
electrodes (one positive and one negative comprise a pair) on 
each of the four sites having the highest measured amplitudes. 
It is the unique EEG pattern of the individual, however, that 
is the key to the most efficient treatment. The determination of 
treatment sites applies to any diagnostic category of neuro 
logical dysfunction and the determination is individualized 
by the quantitative data from each individuals brainwave 
data. Therefore, it is not possible to specify a standard set of 
sites for any given, or all, diagnostic categories. However, 
there is a broad diagnostic classification called EEG-slowing 
and that this category can permit the selection of predeter 
mined sites from which to direct the treatment of choice. 
Therefore, given the above information one of ordinary skill 
would understand how to select a region of the brain for 
treatment on a Subject by Subject basis. 
The neurostimulation signal is administered by modulat 
ing a high frequency component, which can be further pulse 
width modulated for control of the energy level, with a low 
frequency carrier. It is the preferred intent of the present 
invention to “disentrain the brain's electrical activity, that is, 
to not target or lock into a particular frequency, but rather to 
redistribute existing energy to all frequencies in the normal 
spectra of the brain EEG in a typically uniform manner. 
However, the present invention does not preclude the utiliza 
tion of the neurostimulation signal for the purposes of 
entrainment. 
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The present invention also embodies a method of focusing 
a neurostimulation signal directly on a suspected dysfunc 
tional region of the brain. This is possible because tissue 
impedances are minimized by the design of the neurostimu 
lation signal. The neurostimulation signal possesses a greater 
ability to directly reach damaged regions of the brain rather 
than simply following the outer-most tissues around the scalp 
and thereby bypassing the damaged region of the brain. 
Another advantage is achieved by inducing the neurostimu 
lation signal directly into EEG sensors. This advantage is that 
the neurostimulation signal can be strategically placed to 
present a conduction path through the damaged region of the 
brain, while concurrently measuring the EEG signal at the 
dysfunctional regions, thus providing a direct link between 
the measured EEG signals and the neurostimulation signals 
being delivered directly to the dysfunctional region. 
A method for treating a subject with the method of the 
present invention preferably includes the generation of an 
electrical neurostimulation signal characterized by a high 
frequency pulse train modulated by a low frequency carrier 
signal. A means of providing for variable levels of electrical 
power may be accomplished by using either pulse width 
modulation of the high frequency pulse train, as in the pre 
ferred embodiment of the present invention, or variable 
amplitudes of the same pulses. Preferably, the frequency of 
the high frequency pulse train is at least one order of magni 
tude greater than the frequency of the low frequency carrier 
signal. It is preferred that the high frequency pulse be in the 
range of 43 to 1,000,000 hertz. It is more preferred that the 
high frequency pulse be in the range of 1,000 to 100,000 
hertz. It is even more preferred that the high frequency pulse 
be in the range of 10,000 to 20,000 hertz. It is most preferred 
that the high frequency pulse be 15,000 hertz. 
The low frequency carrier signal is variably related to 
critical frequency components of the EEG power spectral 
density, determined from statistical analysis of amplitudes 
and variability. The low frequency carrier signal is deter 
mined from information obtained by measuring EEG activity 
at a reference site or sites that generally corresponds with the 
location of suspected brain dysfunction, and the low fre 
quency carrier signal is dynamically changed as a function of 
time to prevent entrainment. This is performed by changing 
the frequency offset (as described below) at predetermined 
time intervals. It is preferred that the low frequency carrier 
signal be typical of a brainwave EEG. It is more preferred that 
the low frequency carrier signal be in the range of 1-42 hertz. 
The combination of (1) the high frequency pulse train as it 
is modulated by (2) the low frequency carrier signal, hence 
forth referred to as an AMPWM signal, provides a means of 
minimizing the effect of tissue impedances of the head. How 
ever, no limitation of the present invention to AMPWM sig 
nals alone is intended by this abbreviation. Any signal that 
possess both (1) and (2) as defined above is intended to be 
encompassed by the present invention. 
In general, as will be discussed in greater detail in Subse 
quent sections of this disclosure, the electrical impedance of 
tissues of the head decreases with increased electrical signal 
frequency. Thus, the high frequency pulse train component of 
the AMPWM signal passes through the head tissues with less 
attenuation than the low frequency carrier signals typically 
used in already known neurostimulation methods. Further, 
the low frequency carrier signal component of the neuro 
stimulation signalinessence serves to turn on and off the high 
frequency signal component with a frequency that is gener 
ally related to the range of frequencies present in an EEG 
signal. Thus, the low frequency carrier signal component may 
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be produced at frequencies commonly used for therapeutic 
purposes in neurostimulation devices, such as entrainment or 
disentrainment. 
Some neurological dysfunctions that may be treated by the 
present invention include traumatic brain injury, post trau 
matic stress disorder, post stroke paralysis, post traumatic 
brain injury paralysis, cerebral palsy, headache, depression, 
post chemotherapy cognitive, mood and fatigue disorder, 
fibromyalgia, memory loss, coma, attention deficit disorder, 
etc. However, this list is not intended to be exclusive. 
The method preferably comprises taking a first measure 
ment of the EEG of a subject afflicted with at least one type of 
the neurological dysfunction in order to obtain EEG results 
and evaluating the obtained EEG results to determine whether 
any region of the Subject’s brain possesses irregular activity 
as compared to other regions of the Subjects brain. It is 
preferred that the subject be a mammal and, more preferably, 
a primate. It is most preferred that the subject be a human 
being. It is also preferred that the irregular activity be deter 
mined by comparing the EEG signals from a region of the 
subjects brain with the EEG signals from the remaining 
regions of the subjects brain. It is also preferred that the EEG 
signals are obtained from more than one region of the Sub jects scalp. It is even more preferred that the EEG signals be 
obtained from at least 21 regions of the subject’s scalp that 
correspond to 21 regions of the subjects brain. It is preferred 
that the regions be selected according to the International 
10-20 EEG Site Placement Standard. 
A determination of a dominant frequency of the Subjects 
brain is made from the evaluating the EEG results from the 
regions of the subject’s brain that possess irregular activity. 
Preferably, the evaluation involves the correlation of the EEG 
signals into a graphic image of the Subject's brain. Even more 
preferably, the graphic image is evaluated and new EEG 
signals from the Subject's brain are taken in order to ensure 
that the first EEG signals were accurate and in order to deter 
mine a dominant frequency from the regions of the Subjects 
brain that have been confirmed as possessing irregular activ 
ity. 
Finally, the method comprises an administration of an anti 
neurological dysfunction therapy to the Subject. The anti 
neurological dysfunction therapy comprises inducing a neu 
rostimulation signal directed to the regions of the Subjects 
brain that possess irregular activity for a time Sufficient to 
normalize the EEG signals of the regions of the subjects 
brain that possess irregular activity. 
It is preferred that the time be between one second and one 
hour. It is more preferred that the time be between 1 and 30 
minutes. It is even more preferred that the time is between 1 
minute and 10 minutes. It is even more preferred still that the 
time be between 1 minute and 3 minutes. It is still more 
preferred that the time be between 1 second and 30 seconds. 
It is most preferred that the time be between 1 second and five 
seconds. 
Additionally, further EEG signal measurements from the 
regions of the Subject's brain that possess irregular activity 
are monitored during the administration of the therapy and the 
neurostimulation signal is adjusted based on any detected 
changes in the additional EEG signal measurements. The 
normalization of the EEG signals from the regions of the 
Subject’s brain that possess irregular activity results in an 
alleviation of the symptoms of the neurological disorders. 
The neurostimulation signal comprises a carrier frequency 
which comprises the dominant frequency and the frequency 
offset. It is preferred that the frequency offset be between -10 
and 20 hertz. 
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It is preferred that the normalization of the regions of the 
Subject's brain that possess irregular activity result in these 
regions transmitting EEG signals which are close to the pre 
determined frequency and amplitude expected for those 
regions of the subjects brain. It is even more preferred that 
these regions transmit EEG signals at the predetermined fre 
quency and amplitude expected for those regions of the Sub 
ject's brain after the treatment. 
The Subject may require multiple exposures to the method 
in order to achieve an alleviation of the symptoms he or she 
suffers from the neurological dysfunctions. It is preferred that 
the multiple exposures remain in the range of 1 to 40 expo 
Sures. However, more exposures are permitted, if required. It 
is more preferred that the exposures remain in the range of 10 
to 30 exposures. It is more preferred that the exposures remain 
in the range of 5 to 10 exposures. Additionally, it is preferred 
that a repeated use of the method be avoided within 24 hours 
of a previous use of the method. However, if required, it is 
possible to treat more than one region of the subject’s brain (if 
more than one region of the Subjects brain possesses irregu 
lar activity) in one treatment session. 
Additionally, the Subject may be medicated, sedated, or 
unconscious during the administration of the method. How 
ever, it is preferred that the subject be in none of these con 
ditions. 
Regarding the application of the neurostimulation signal 
itself, after the identification of regions the subjects brain 
which possess irregular activity, neurostimulation treatment 
is accomplished by placing EEG sensors in an arrangement 
that allows for the measurement of the EEG activity from the 
dysfunctional region, as well for providing a Successful deliv 
ery of current from the EEG sensors into a system ground. 
The computer-controlled system in the preferred embodi 
ment of the present invention acquires EEG signal data from 
the sensor sites and conducts an analysis of the EEG signal 
data to determine the frequency of the low frequency carrier 
signal component of the AMPWM signal. 
The AMPWM signal can be transmitted to the subject 
through a plurality of neurostimulation delivery modes. In a 
preferred embodiment of the present invention the preferred 
mechanism of delivery is accomplished by inducing the 
AMPWM signal into the EEG sensors through inductive cou 
pling. Another preferred mechanism is to use the AMPWM 
signal to drive a light-generating component. Such as a light 
emitting diode, to provide a photic stimulation signal that 
may be delivered to the patient through the optic nerve. 
Another preferred embodiment involves the simultaneous 
use of stimulation delivery by inducing the AMPWM signal 
into the EEG sensors through inductive coupling and drive a 
light-generating component, such as a light emitting diode, to 
provide a photic stimulation signal. In essence, this is a com 
bination of previously discussed embodiments. 
Lastly, it is preferred that EEG leads be placed on the scalp 
regardless of what stimulation method is used because the 
apparatus and method preferably measures EEG during 
stimulation delivery, and uses these EEG measurements to 
drive neurostimulation signal parameters. 
In a preferred embodiment of the present invention, deliv 
ery mode is selectable to account for different levels of sen 
sitivity and tolerance in patients. It is also possible to com 
pletely automate the process of transmitting the 
neurostimulation signal and the monitoring of the EEG signal 
data from the EEG sensors. 
As stated above, it is preferred that the EEG signals from 
the subject be measured at typically 21 different scalp loca 
tions and it is preferred that power spectral density computa 
tions are performed on the obtained EEG signals. These com 
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putations break the measured analog EEG signals into 
frequency domain data such as a Fourier series of discrete 
frequency components, which is limited to 1-42 Hertz 
(greater signal components exist and could be utilized, but the 
1-42 Hertz range is typically considered clinically useful). 
However, other methods of obtaining the frequency domain 
data are acceptable (such as the use of wavelet analysis). 
In analyzing EEG signal data, frequency bands are com 
monly used. For example, the “delta” band is typically 1-4 
Hertz, the “theta' band is 5-7 Hertz, and so on. For each site, 
the total amplitude associated with each discrete frequency 
component is assigned to proper bands, providing a measure 
of the EEG band energy for each of the aforementioned sites. 
From this, a graphic “image' is generated where colors rep 
resent amplitudes. From this image, the clinician can see EEG 
band activity related to regions of the brain, and based on 
clinical knowledge, can determine if a region has unusual or 
abnormal activity. 
Accordingly, the neurostimulation phase of the process 
(i.e. treatment) is administered to correct regions of abnormal 
activity. The administration of the neurostimulation signal is 
preferably performed after the imaging process described 
above is completed. The clinician preferably applies EEG 
sensors to regions of the Scalp that relate to the regions of 
suspected dysfunction and the EEG signal data is preferably 
re-measured for a period long enough to provide power spec 
tral density data (as in the imaging process). The frequency 
domain data is then sorted, and the frequency that exhibits the 
highest amplitude is designated the "dominant frequency’. 
According to clinician chosen stimulation time and frequency 
parameters, a neurostimulation signal is generated that has a 
“carrier frequency” that is determined by the formula: CAR 
RIER FREQUENCY=DOMINANT FREQUENCY+FRE 
QUENCY OFFSET. 
The parameters the clinician uses are (1) stimulation inten 
sity, (2) the times that the stimulation signal is turned on in the 
treatment cycle (as well as the number of times), (3) the 
duration that each stimulation signal is turned on, the leading 
frequency of each stimulation event, and (4) the phase offset 
of each stimulation event. Intensity is defined by the pulse 
width-modulation duty cycle, and ranges from 0 (no "on 
time') to 100% (no “off-time'). Thus, an intensity of 50% 
would have a duty cycle such that “on-time' is equal to 
“off-time' in each pulse cycle. The number of stimulation 
cycles and the times that the stimulation turns on is entirely 
clinician driven. However, it is preferred ranges that the 
stimulation cycles range between 1 Stimulation event up to 
50. It is preferred, however, that no more than 20 different 
stimulation events be used per session. The preferred leading 
frequency is already defined to range between -10 and 20 Hz. 
Preferred Phase offset ranges from -180 to 180 Hz. 
In this formula, “frequency offset is preferably selected 
from the range of -40 to 40 Hertz and more preferably from 
-10 and 20 Hertz. 
The offset is chosen by clinical experience, therefore, one 
of ordinary skill in the art would recognize how to choose an 
offset. However, the clinician generally picks the largest off 
set (i.e., +20 Hz) to see ifa response is elicited. If no response 
is elicited, lower offsets will be tried until a response is 
obtained. The clinician’s choice of parameter values is typi 
cally driven by a selection of choices that cause the subject to 
react, but yet do not cause an “over-reaction' which is an 
adverse effect characterized by short-term fatigue, headache, 
etc 
All of the preferred neurostimulation parameters to be 
considered are defined below. Values of these parameters are 
chosen based on clinician experience, and are selected in a 
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manner that is meant to cause a reactive therapeutic effect 
without causing the subject to over-react. The selection of 
these values is further driven by subject condition and symp 
tomatic presentation. For example, a Subject with mild trau 
matic brain injury may be able tolerate a longer (in duration) 
than average stimulation application without Suffering an 
adverse effect. However, a subject with fibromyalgia with 
severe fatigue may only tolerate a very short (in duration) 
stimulation burst at the lowest intensities possible. The ranges 
of values for these parameters are provided for the clinician to 
choose based on experience, patient condition and symptom 
atic presentation, thus no preferred or optimal values exist. 
These parameters include: 
Intensity. This is a measure of the pulse width modulation 
signals duty cycle. This provides a variation on the time 
averaged current delivered to the stimulation mechanisms 
(i.e. the EEG lead inducing circuit and the photic stimulators). 
Duration. This is a measure the time in seconds that a 
neurostimulation event (i.e. a period of stimulation signal 
output) lasts. This can range from 1 second to 1,200 seconds 
in the preferred embodiment. 
Start Time This is the time in seconds after the beginning 
of a neurostimulation treatment session begins when a neu 
rostimulation event starts to occur. There is no specific limi 
tation on this, that is, the start time could begin at any time 
after the treatment session begins. Before the start time 
occurs, the system is simply measuring EEG and this could, 
theoretically, go on indefinitely. 
Leading Frequency and Phase Offset are previously 
defined. 
By adding the frequency offset to the dominant frequency, 
a carrier frequency is created that is always different than the 
dominant frequency. This neurostimulation signal is then 
either induced in the EEG sensors attached to the subjects 
Scalp or the neurostimulation signal is used to drive light 
emitting diodes for photic stimulation purposes. The duration 
of the signal, along with other parameters (as described 
above) such as intensity and phase offset (in the case of LEDs 
for photic stimulation—a phase offset causes the LEDs to 
flash out of synchronization with each other) are determined 
by the clinician's chosen treatment protocol. 
As described above, the neurostimulation signal can be an 
amplitude modulated pulse-width modulation signal. A 
graphic representation of the signal is shown in FIG. 2. In 
other words, the carrier frequency simply turns an electric 
signal on and offin a way that a square-wave pulse train is 
generated with a frequency equal to the carrier frequency. 
Thus, in a period (period=1/frequency) of this pulse train, 
there will be an amount of time that the electric signal is “on” 
and an amount of time when the signal is “off” (see FIG. 2). 
During the time that the carrier signal is “on”, the electricity 
is further pulsed at a very high frequency. A pulse width 
modulator is used to control this high frequency pulsing. By 
varying the pulse width, the average current applied is varied. 
This is what varying the “intensity” means. With a very low 
duty cycle, there is very little average current and thus the 
neurostimulation signal has very low intensity. Conversely, a 
higher duty cycle delivers more current and thus the intensity 
increases. A 100% duty cycle means that there is no “high 
frequency off time', and thus the entire neurostimulation 
signal is a simple square wave pulse train with frequency 
equal to the carrier frequency. 
Regarding the apparatus, FIG. 3 presents a model of the 
apparatus of the present invention. In FIG. 3, tissue imped 
ance 6 is represented by a parallel combination of a simple 
resistor 1 and a simple capacitor 2. A Voltage source 3 pro 
vides electricity at a supply electrode 4 interfaced at a sub 
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jects skin 7, with the electricity passing through the tissue 
impedance 6 and ultimately being returned to a common 
ground 5 potential. Following fundamental circuit analysis, 
the equivalent impedance (Zor-Evr) of the circuit is 
given by the formula: 
ZEQUIVALENT = 1 + 2fRC 
In this formula, the resistance is given by the nomenclature 
R, capacitance by C and frequency by f. This equation clearly 
shows that as the frequency of the signal increases, the overall 
impedance of the system decreases despite the level of imped 
ance from the resistor 1 being constant. Although the imped 
ances of the composite tissues of the head are considerably 
more complex and require a far more Sophisticated model to 
accurately describe current flows, this model provides a 
simple analogy and approximately describes the effect, and is 
a fundamental basis for the disclosure of the present inven 
tion. 
The effects of applying electrical energy to brain tissues, 
the electrical energy is known in this disclosure as a neuro 
stimulation signal, are well established in the medical litera 
ture and in other teachings, and will not be expounded upon 
here. 
As stated above, the invention is also directed to an appa 
ratus for neurostimulating a Subject. The apparatus comprises 
a computing device that is operatively coupled to a neuro 
stimulator, and a series of EEG sensors that are coupled to the 
neurostimulator. Examples of appropriate computing devices 
are microprocessors or computers. However, any processing 
unit can be used in the present invention as a computing 
device. These components are coupled to each other via elec 
trical conduction paths. For example, the neurostimulator 
could be coupled to the computing device with RS232 cable, 
USB cable, etc. Further, the EEG sensors can be coupled to 
the neurostimulator with an electrical connector. However, in 
both instances, other methods of coupling the components are 
acceptable. The EEG sensors are configured (1) to be attached 
to the subject, (2) to monitor EEG signals of a subject, and (3) 
to administer neurostimulation signals to the Subject. Addi 
tionally, the EEG sensors comprise at least one positive con 
tact, at least one negative contact, and at least one ground 
COntact. 
The apparatus further comprises a biopotential acquisition 
device, at least one filtering unit, an isolation amplifier, and a 
microcontroller. A preferred microcontroller is the Toshiba 
TMP95EY64. However, any comparable microcontroller 
may be used. The biopotential device is operatively coupled 
to the computing device, and the neurostimulator is config 
ured to transmit the biopotential data and EEG signal data to 
the biopotential acquisition device. These components may 
be coupled together in the manner set forth previously or in 
any additional manner that permits their correct usage. Addi 
tionally, the biopotential acquisition device is configured to 
transmit the EEG data and biopotential data through at least 
one circuit or numerical filter and through an isolation ampli 
fier which is operatively coupled to the microcontroller. Fur 
thermore, it is preferred that the isolation amplifier be capable 
of performing “notch' filtering (i.e., eliminate 60 Hz line 
noise) and it can be selected from any component found on 
the market. It is preferred that it be a Burr-Brown ISO-100. 
It is preferred that the filtering unit be selected from the 
group consisting of a circuit configured to filter data and a 
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numerical filter. It is also preferred that the biopotential acqui 
sition device is a biopotential amplifier or a high resolution 
analog-to-digital converter. 
The neurostimulator comprises a biopotential acquisition 
unit comprising an electric circuit configured to acquire bio 
potential data from the EEG signals obtained by the EEG 
sensors attached to the Subject. The biopotential acquisition 
unit is also configured to analyze and store the acquired 
biopotential and EEG data with computational means and it is 
operatively coupled to the neurostimulator. The neurostimu 
lator also comprises a transmission unit configured to trans 
mit the biopotential and EEG data from the neurostimulator 
to the computing device and an I/O (input/output) unit con 
figured to adjust for a time lag in the biopotential and EEG 
data being transmitted. The neurostimulator also comprises at 
least one Switching unit configured to manage a neurostimu 
lation signal. 
It is preferred that the subject is a mammal. It is further 
preferred that the subject be a primate and even more pre 
ferred that the subject is a human being. It is also preferred 
that the Switching device is a transistor. 
Additionally, the neurostimulator comprises an inductor, 
acting as a transformer, whereas the stimulation signal is 
induced in the neurostimulator by inducing electrical current 
into the inductor, which further induces electrical current in 
the EEG sensors via electromagnetic coupling, and thereby 
into the subject. 
The neurostimulator can further comprise an optical unit 
which further comprises a set of light generating devices 
located in close proximity to the pupils of the subject. It is 
preferred that the light generating devices are light-emitting 
diodes. 
With reference to the accompanying FIG. 1, a preferred 
embodiment of the present invention is described where a 
computing device 8 is operatively coupled to a peripheral 
device henceforth referred to as a neurostimulator 9, such as 
through a peripheral cable 10. However, a peripheral cable is 
not the only method of coupling the neurostimulator to the 
computing device. The neurostimulator 9 further comprises a 
series of electrical conductors henceforth referred to as EEG 
sensors 11. The EEG sensors 11 consist of at least one positive 
lead 12, one negative lead 13 and one ground lead 14. How 
ever, the at least one positive lead 12, one negative lead 13. 
and one ground lead 14 may also be incorporated into one 
SenSOraS COntactS. 
In a preferred embodiment of the present invention, 
employing multiple sets of EEG sensors II simultaneously 
and multiple biopotential acquisition devices 15 can accom 
plish acquisition of EEG signals from multiple sites on the 
scalp. For clarity, the preferred embodiment is described with 
for acquisition of EEG signal from one scalp site. All EEG 
sensors 11 are connected to the neurostimulator 9 via EEG 
sensor connectors 17. 
The neurostimulator 9 can further comprise, as a possible 
means of delivering the stimulation signal, an optical unit 16 
that is electrically coupled to the neurostimulator 9 via optical 
device sensors connectors 19. The optical unit 16 can be 
connected to the neurostimulator 9 by an optical device cable 
18. However, other means of connecting the optical unit to the 
neurostimulator are acceptable. The optical device further 
comprises light generating devices 20 located to be in close 
proximity to the subject’s eyes. In the preferred embodiment, 
the light generating devices 20 are light emitting diodes 21. 
The neurostimulator 9 is operated by any number of pos 
sible power Supply 22 Sources. To assure electrical isolation 
for the patient’s safety, an isolated power supply 23 is utilized 
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in the preferred embodiment. Further, the neurostimulator 9 is 
housed in a protective outer enclosure 24. 
The neurostimulator 9 preferably internally comprises the 
biopotential acquisition device and the biopotential acquisi 
tion device is preferably designed to acquire biopotential data 
from EEG signal data, specifically patient EEG, to provide a 
means for analysis and data storage of the biopotential data 
through computational means, generate a neurostimulation 
signal and deliver the neurostimulation signal to the patient. It 
is preferred that a Teledyne A110-2 amplifier be used. 
In a preferred embodiment of the present invention, EEG 
signals are acquired with EEG sensors 11 attached to a 
patient’s scalp. At the end of the EEG sensors 11 attached to 
the patient are contact electrodes 25. The EEG signal is deliv 
ered to the neurostimulator 9 via the EEG sensors 11, con 
nected to the biopotential acquisition device 15 through EEG 
lead connectors 17 and operatively coupled to a biopotential 
acquisition device 15 Such as a biopotential amplifier or high 
resolution analog-to-digital converter. To minimize the effect 
of external electrical noise, any number of circuit or numeri 
cal filters 26 may be employed in the preferred embodiment. 
To assure patient safety, the biopotentials are passed through 
an isolation amplifier 27. The output of the biopotentials, after 
passing through the biopotential acquisition device 15, filters 
26 and isolation amplifier 27 is acquired by a microcontroller 
28 through analog-to-digital ports 29. The microcontroller 28 
is operatively coupled to the computing device 8. One method 
of coupling the microcontroller to the computing device is to 
use a peripheral cable 10. Control of the neurostimulator 9 is 
accomplished by communication between the microcontrol 
ler 28 and the computing device 8. Further, the objective of 
biopotential data analysis and storage is accomplished com 
putationally via communication between the microcontroller 
28 and the computing device 8. 
After analysis of the acquired biopotential, that is, the EEG 
signal, the computing device 8 communicates proper stimu 
lation signal parameters, in accordance with the present 
invention, to the microcontroller 28. These parameters 
include signal energy level, frequency of the low frequency 
component of an AMPWM signal, phase offset of multiple 
signals, start time, frequency offset and duration through a 
user interface. Utilizing a digital-to-analog port 30 on the 
microcontroller 28, the stimulation signal is output from the 
microcontroller 28 to transistors 31 or similar switching 
devices capable of managing the current levels of the stimu 
lation signal. Depending on the mode of Stimulation chosen 
by a clinician, the stimulation signal will be routed to the 
different means of stimulation signal delivery, alone or in 
combination. The parameters for the clinician’s choice are set 
forth above. 
If optical stimulation is desired, the stimulation signal will 
be sent to the optical unit 16 featuring the light generating 
devices 20 to be worn by the patient. Any unit capable of 
emitting light may be used as a light generating device. This 
includes, but is not limited to a LED, a lightbulb, a low-power 
laser, etc. Alternately, if EEG lead 11 stimulation is desired, 
where the stimulation signal is delivered to the patient's scalp 
via the attached electrodes 25, then the stimulation signal is 
sent to an inductor 32 which is designed to induce current in 
the EEG sensors 11 from the stimulation signal generated by 
the microcontroller 28. In the preferred embodiment of the 
present invention, a plurality of stimulation delivery modes is 
warranted to allow for clinician choice to further effect suc 
cessful treatment based on individual patient needs. 
To assure patient safety, all electronics in the neurostimu 
lator 9, including the biopotential acquisition device 15, the 
filter 26, the isolation amplifier 27, the microcontroller 28 and 
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the transistors 31 are supplied electricity by the aforemen 
tioned isolation power supply 23. 
Finally, regarding the coupling of the components, if a 
computing device is used it is preferably operatively coupled 
to the processor of the neurostimulator via any of a number of 
means of commonly used peripheral communications tech 
niques, such as serial communication, USB port communi 
cation or parallel communication 10. All remaining electron 
ics are preferably operatively coupled to the processing 
device (e.g. microcontroller) in the neurostimulator. The data 
acquisition circuit preferably comprises the biopotential 
acquisition device 15, filters 26 and isolation circuitry (ampli 
fier) 27. The isolation amplifier is preferably coupled to an 
analog-to-digital input port on the microcontroller 28, via 
electrical conduction paths. Such as wires or printed circuit 
board conductors. The filters 26 are preferably operatively 
coupled to the isolation amplifier 27 via electrical conduction 
paths such as wires or printed circuit board conductors. Fur 
ther, the biopotential acquisition device 15 is preferably 
operatively coupled to the filters 26 via electrical conduction 
paths such as wires or printed circuit board conductors. 
EEG leads 11 are preferably coupled to the biopotential 
acquisition device 15 via electrical connectors 17, providing 
conduction of EEG electricity at the scalp to the biopotential 
amplifier 15. 
A stimulation circuit is preferably coupled to a digital-to 
analog port 30 on the microcontroller, in all cases via electri 
cal conduction paths. Such as wires or printed circuit board 
conductors. It is preferred that an isolated power supply 23 
Supplies all operative power for neurostimulation outputs 
such as that to the optical device 16 or the EEG lead stimu 
lation inducing circuitry 32. Electrical output from the digi 
tal-to-analog port30 is preferably conducted to a transistor 31 
that is further coupled to the isolated power supply 23. When 
a signal is received at the base of the transistor 31 from the 
microcontroller 28, the transistor operates to switch on elec 
tricity from the isolated power supply 23 which is further 
conducted via electrical coupling to the inductor (stimulation 
inducing circuitry) 32. Current flow in the inductor 32 
induces a current in the EEG lead, as described in the speci 
fication. 
Alternately, for photic stimulation, the isolated power Sup 
ply 23 is preferably coupled via electrical coupling to two 
more transistors 31, which are preferably operatively coupled 
via electrical coupling to independent digital-to-analog ports 
30 on the microcontroller 28. Electricity conducted from the 
digital-to-analog ports 30 to the base of the transistors 31 in 
the photic stimulation circuit has the effect of switching on 
these transistors, further allowing for conduction of electric 
ity to the photic stimulation devices, such as LEDs 21. The 
photic stimulation devices are preferably coupled to the tran 
sistors 31 via electrical connectors 19, thus providing for 
current flow to the photic stimulation devices such as LEDs 
21. 
Finally, it is preferred that the apparatus operate on a 12 
Volt power Supply. It is more preferred that the apparatus 
operate on a 6 volt power supply. It is most preferred that the 
apparatus operate on a power Supply equivalent to the lowest 
power Supply requirement of the components used. 
With reference to FIGS. 5-7, a form of electrical signal for 
stimulating tissues is disclosed wherein an electrical signal of 
relatively high frequency (FIG. 1) is amplitude modulated by 
an electrical signal of relatively low frequency (FIG. 6), com 
bining to form an electrical signal of the general form shown 
in FIG. 7. As discussed above, using pulse width modulation 
for the purpose of varying the duty cycle of the electrical 
signal of relatively high frequency, the time-averaged current 
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deliverable by that signal can be controlled Hence, FIG. 7 
shows an example of one embodiment of an amplitude modu 
lated pulse width modulated (AMPWM) signal in which the 
signal of relatively low frequency shown in FIG. 6 and the 
signal of relatively high frequency shown in FIG. 5 form an 
AMPWM signal shaped similar to a square wave pulse train. 
However, an AMPWM signal may combine signals of 
shapes other than square waves. For example, FIG. 8 shows a 
signal of relatively low frequency that has a general sinusoi 
dal form. When used to amplitude modulate a signal of rela 
tively high frequency, as shown in the example of FIG. 1, a 
resulting AMPWM signal equivalent is that shown in FIG.9. 
An AMPWM signal may also be created from multiple 
relatively low frequency components. A signal with multiple 
frequency components can be created using methods such as 
inverse Fourier Transform theory. FIG. 10 shows an example 
of a composite sinusoidal signal with three relatively low 
frequency components that are created using an inverse Fou 
rier Transform. Such relatively low frequency components 
may be selected to provide therapeutic electrical stimulation. 
One anticipated benefit of creating Such a composite signal is 
to provide for therapeutic electrical stimulation that has mul 
tiple frequency-dependent beneficial effects on the tissues to 
which it is applied. When a composite signal Such as that 
illustrated in FIG.10 is used to amplitude modulate a signal of 
relatively high frequency, as shown in the example of FIG. 1, 
a resulting AMPWM signal equivalent is that shown in FIG. 
11. 
Various apparatus and circuits for creating and using an 
electrical signal for stimulating tissues such as an AMPWM 
signal are disclosed above. Here, an improved apparatus is 
provided, which provides for the generation of electrical tis 
sue stimulation signals, such as AMPWM signals, that reduce 
tissue impedance and increase depth of signal penetration. A 
first embodiment of a tissue stimulation apparatus for provid 
ing an electrical tissue stimulation signal that reduces tissue 
impedance and increases depth of signal penetration is shown 
in FIG. 12, as comprising an electrical stimulation device 101 
and an external computing device 102 is provided. Power for 
the electrical stimulation device 101 may be provided by an 
external power source 105. Such as a line connection or an 
adapter for providing a conditioned electrical source, electri 
cally coupled to the electrical stimulation device 101 through 
a power connector 111. 
Internally, the electrical stimulation device 101 may 
include a battery charger and switching circuit 107 electri 
cally coupled to the power connector 111, enabling the 
receipt of electricity from the external power source 105. A 
battery 108 may also be electrically coupled to the battery 
charger and switching circuit 107. The battery 108 may fur 
ther be connected to other circuits of the electrical stimulation 
apparatus through the battery charger and Switching circuit 
107 and used to provide electrical power to the other circuits 
at times when isolation from line current is required or advan 
tageous for operation of the apparatus, such as in times when 
the apparatus is being used to provide electrical stimulation to 
a Subject. In practice, electrical isolation may be accom 
plished through a Switching portion of the battery charger and 
switching circuit 107, which may be further electrically 
coupled to a controller or processor 103 configured to control 
various functions of the electrical stimulation device 101 such 
as electrical signal generation and as is further described 
herein. Programmed firmware, associated with processor 
technologies, for example, may provide for electrical signals 
to be sent from the processor 103 to control the switching 
portion of the battery charger and switching circuit 107 and to 
electrically decouple the electrical stimulation device 101 
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from the external power source 105 when isolation is required 
or desirable. At times when isolation is not required or desir 
able, such components as the processor 103, external power 
source 105 and battery charger, and switching circuit 107 may 
be used to recharge the battery 108 in preparation for subse 
quent use. In other words, the processor 103 may be config 
ured to command the Switching portion of the battery charger 
and switching circuit 107 to couple the external power source 
105 to the battery 108 when isolation of the electrical stimu 
lation device 101 is not required or desirable and to decouple 
the external power source 105 from the battery 108 when 
isolation is required or desirable. This coupling may be 
accomplished either as a result a signal being sent to a pro 
cessor 103 arising from a manual input such as the manual 
decoupling of an external power source 105 from line power, 
or automatically arising from a software signal being sent to 
a processor 103 whenever an operator utilizes a software 
interface for using the apparatus to electrically stimulate a 
subject. In other words, the processor 103 may be pro 
grammed to automatically decouple external power in 
response to an operators use of a software interface to use the 
apparatus to electrically stimulate a subject. 
The battery 108 or other power source may subsequently 
energize a power regulation circuit 109 that further provides 
conditioned power to other circuits of the electrical stimula 
tion device 101 and a common reference ground that may be 
used by all circuits. A ground connector 112 may be used to 
provide electrical coupling to external circuits, such as those 
described herein, for common grounding purposes. 
As is also shown in the embodiment of FIG. 13, condi 
tioned power from the power regulation circuit 109 may 
further be used to energize the processor 103, whereupon a 
circuit for creating or generating an electrical signal for 
stimulating tissues is realized. This stimulation signal gen 
eration circuit may comprise the processor 103, a digital-to 
analog (D/A) converter 104, a signal conditioning and ampli 
fication circuit 106, a stimulation switching circuit 110, and a 
first ground switching circuit 119. Further, the tissue stimu 
lation apparatus may include an external computing device 
102 coupled to the processor 103 through any suitable com 
puter data cable 118 or similar interface, such as a wireless 
interface. The external computing device 102 may provide 
and be used as a user interface via Software, and may provide 
for communication between a user and the processor 103. 
Such communication comprising the flow of any and all forms 
of data and control signals to set and modify operational 
parameters of the electrical stimulation device 101. In other 
words, the external computing device is programmed to 
exchange data and control signals with the processor and to 
allow a user to modify operational parameters of the electrical 
stimulation apparatus. 
The present invention may be implemented using hard 
ware, software or a combination thereof and may be imple 
mented in one or more computer systems or other processing 
systems. In one embodiment, the invention is directed toward 
one or more computer systems capable of carrying out the 
functionality described herein. An example of Such a com 
puter system is shown at 200 in FIG. 67. 
The computer system 200 includes at least one processor 
204 that is connected to a communication infrastructure 206 
(e.g., a communications bus, cross-over bar, or network). Any 
suitable software embodiments may be used with this exem 
plary computer system, and the invention may be imple 
mented using any Suitable computer system and/or architec 
tures. 
The computer system 200 may include a display interface 
202 that forwards graphics, text, and other data from the 
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communication infrastructure 206 or from a frame buffer (not 
shown) for display on a display unit 230. The computer sys 
tem 200 may also include a main memory 208, preferably 
random access memory (RAM), and may also include a sec 
ondary memory 210. The secondary memory 210 may 
include, for example, a hard disk drive 212 and/or a remov 
able storage drive 214 Such as a floppy disk drive, a magnetic 
tape drive, oran optical disk drive, etc. The removable storage 
drive 214 may be configured to read from and/or writes to a 
removable storage unit 218 in a well-known manner. The 
removable storage unit 218 may include a floppy disk, mag 
netic tape, optical disk, etc., which may be read by and written 
to the removable storage drive 214. The removable storage 
unit 218 may include a computer usable storage medium 
having stored therein computer software and/or data. 
In alternative embodiments, the secondary memory 210 
may include other similar devices for allowing computer 
programs or other instructions to be loaded into computer 
system 200. Such devices may include, for example, a remov 
able storage unit 222 and an interface 220. Examples of such 
may include a program cartridge and cartridge interface (Such 
as that found in video game devices), a removable memory 
chip (such as an erasable programmable read only memory 
(EPROM), or programmable read only memory (PROM)) 
and associated Socket, and other removable storage units 222 
and interfaces 220, which allow software and data to be 
transferred from the removable storage unit 222 to the com 
puter system 200. 
The computer system 200 may also include a communica 
tions interface 224. The communications interface 224 may 
be configured to allow software and data to be transferred 
between the computer system 200 and external devices. The 
communications interface 224 may include a modem, a net 
work interface (such as an Ethernet card), a communications 
port, a Personal Computer Memory Card International Asso 
ciation (PCMCIA) slot and card, etc. Software and data trans 
ferred via communications interface 224 are in the form of 
signals 228, which may be electronic, electromagnetic, opti 
cal or other signals capable of being received by communi 
cations interface 224. These signals 228 are provided to com 
munications interface 224 via a communications path (e.g., 
channel) 226. This path 226 carries signals 228 and may be 
implemented using wire or cable, fiber optics, a telephone 
line, a cellular link, a radio frequency (RF) link and/or other 
communications channels. In this document, the terms "com 
puter program medium' and "computer usable medium' are 
used to refer generally to media Such as a removable storage 
drive 214, a hard disk installed in hard disk drive 212, and 
signals 228. These computer program products provide Soft 
ware to the computer system 200. The invention may include 
Such computer program products. 
Computer programs (also referred to as computer control 
logic) are stored in main memory 208 and/or secondary 
memory 210. Computer programs may also be received via 
communications interface 224. Such computer programs, 
when executed, enable the computer system 200 to perform 
according to the features of the present invention, as dis 
cussed herein. The computer programs, when executed, 
enable the processor 204 to perform according to the features 
of the present invention. Accordingly, such computer pro 
grams serve as controllers of the computer system 200. 
In an embodiment where the invention includes the use of 
Software, the Software may be stored in a computer program 
product and loaded into computer system 200 using the 
removable storage drive 214, the hard drive 212, or the com 
munications interface 224. The control logic (software), 
when executed by the processor 204, causes the processor 
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204 to perform according to the functions of the invention as 
described herein. In another embodiment, the invention may 
be implemented primarily in hardware using, for example, 
hardware components, such as application specific integrated 
circuits (ASICs). Implementation of the hardware state 
machine so as to perform the functions described herein will 
be apparent to persons skilled in the relevant art(s). 
In yet another embodiment, the invention may be imple 
mented using a combination of both hardware and software. 
In Some embodiments, and as shown in FIG. 12, generating 
an electrical signal for stimulating tissues begins with signal 
parameters being established through various software meth 
ods used in an external computing device 102 and communi 
cated to a processor 103 via any suitable data cable 118 or 
similar interface. Such as a wireless interface. In other words, 
the external computing device 102 is configured to establish 
parameters of the electrical signals generated by the electrical 
stimulation device 101. Such signal parameters include, but 
are not limited to waveform, frequency components, phase, 
pulse width, duty cycle, and amplitude components such as 
minimum amplitude, maximum amplitude, and offset Volt 
age. Various methods of establishing signal parameters may 
be used with the electrical stimulation device 101. 
Upon establishment of signal parameters in a processor 
103, along with establishment of other operational param 
eters, such as the aforementioned decoupling of an external 
power source 105, signals are sent from the processor 103 to 
a D/A converter 104, whereupon an analog Voltage represent 
ing an electrical signal for stimulating tissues is first achieved. 
The analog voltage is further provided to an electrically 
coupled signal conditioning and amplification circuit 106. 
where a substantially equivalent signal is created with advan 
tageous enhancements such as, but not limited to, increased 
Voltage amplitude, decreased signal-to-noise ratio, and 
increased current capability. 
In some embodiments, provisions may be made to the 
electrical stimulation apparatus for the selective control of the 
delivery of an electrical signal for stimulating tissues to a 
plurality of stimulation connectors 113. A stimulation switch 
ing circuit 110 is electrically coupled to the processor 103. 
whereupon control signals from the processor 103 allow for 
the signal from the signal conditioning and amplification 
circuit 106 to be advantageously switched to any number of 
independent electrical conductors or conduction paths. Fur 
ther, the independent electrical conductors or conduction 
paths are electrically coupled with a first ground Switching 
circuit 119, the first ground switching circuit 119 being fur 
ther electrically coupled to the processor 103. Control signals 
from the processor 103 allow for selective switching of the 
independent conductors to an apparatus ground point, pro 
viding advantageous control of the independent conductors 
use as either a conduction path for an electrical signal for 
stimulating tissues or a ground. Further electrical conduction 
paths are provided for each independent conductor passing 
through a first ground switching circuit 119, with each inde 
pendent conductor terminating at one of a plurality of stimu 
lation connectors 113. 
The apparatus may include a number of electrical conduc 
tors that provide electrical coupling between a number of 
connectors and input/output (I/O) ports of a processor 103 in 
the electrical stimulation device 101 for the embodiments 
shown. Specifically, an auxiliary power Supply connector 114 
may be provided. The apparatus may include a Switch com 
prising an electrical conductor first connected to an auxiliary 
power Supply connector 114 then to a Switch, then via another 
electrical conductor to an auxiliary I/O connector 116. The 
Switch may be used for various purposes to indicate an event 
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to the processor 103. One exemplary purpose is the use of the 
Switch by a Subject receiving electrical stimulation to marka 
point in time of any particular interest. 
The electrical stimulation device 101 may also include a 
plurality of conductors or control I/O connectors 115 that 
provide electrical coupling to I/O ports of the processor 103. 
Specifically, the control I/O connectors 115 may provide 
control signals between the processor 103 and various elec 
trical apparatus or peripheral devices coupled to the electrical 
stimulation device 101, examples of which are described 
further herein. The apparatus may further include a number of 
lead test ports 117 electrically coupled to the processor 103 
for electrically coupling electrical conductors or other cou 
plings, to the processor 103 for the purpose of testing the 
electrical conducting integrity of any combination of Such 
electrical conductors, or other couplings, such as wires com 
bined with sensors, such as surface electrodes, henceforth 
referred to as “leads”, used to conduct electrical energy 
between tissues and the electrical stimulation device 101. 
As is also shown in FIG. 13, the electrical stimulation 
device 101 may include one or more ground leads 120, a 
plurality of stimulation leads 121, and provision at a termi 
nating end of all leads for an electrode 122 adapted to be 
placed on tissues in either an invasive or non-invasive way. 
The apparatus also has provision for one or more external 
stimulation devices, such as an optical device 123, electro 
magnetic device 170, electromechanical device 171 or an 
audio device 172, electrically coupled by one or more exter 
nal stimulation device cables 124. As shown in FIG. 13 the 
external stimulation devices may include an optical device 
123 comprising eyeglasses adapted with illuminating or simi 
lar photic devices, such as light emitting diodes, or with 
displays for showing digital images to a subject undergoing 
therapy. The external stimulation devices may include an 
audio device 172 adapted to play music during therapeutic 
activity. 
In operation, the apparatus of FIG. 13 provides stimulation 
from the electrical stimulation device 101 to tissues disposed 
between stimulation leads 121 and ground leads 120 such that 
an approximate vector path of electrical current flow extends 
between electrodes 122 associated with the stimulation leads 
121 and electrodes 122 associated with the ground leads 120. 
The processor 103 may be programmed to provide control 
signals that selectively control the stimulation Switching cir 
cuit 110 and the first ground switching circuit 119 to cause the 
leads 121 to serve as either stimulation leads delivering 
stimulation or as ground leads serving as ground sources in 
Such a way as to create multiple spatial paths of electrical 
stimulation through tissues. 
In addition, as shown in FIG. 13, stimulation may be pro 
vided by an external stimulation device 123 operatively 
coupled to a stimulation connector 113 that is being used as an 
active stimulation electricity source through control of a 
stimulation Switching circuit 110 by signals from a processor 
103. 
In addition, in the apparatus shown in FIG. 13, electrical 
conducting integrity of any stimulation lead 121, any ground 
lead 20, or any external stimulation device 123 may be tested 
by effecting physical contact between a lead, preferably by 
providing mechanical connection between a leads conduc 
tion interface such as an electrode 122 and a lead test port 117. 
In testing for electrical conducting integrity, a processor 103 
may be selectively used to output an electrical signal of 
known properties to a lead 121 being tested, whereupon the 
electrical signal conducted by the lead being tested can be 
acquired by the processor 103 through a lead test port 117. 
Any number of Suitable analyses may be conducted, where 
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upon processor firmware, for example, makes a comparison 
between the electrical signal of known properties and the 
signal conducted through a lead being tested in order to deter 
mine the electrical conducting integrity of the lead. 
As shown in FIG. 14, a second embodiment of tissue stimu 
lation apparatus for providing an electrical tissue stimulation 
signal that reduces tissue impedance and increases depth of 
signal penetration is shown as comprising an electrical stimu 
lation device 101 and a biopotential acquisition device that 
measures biopotential Voltage in tissue to be stimulated. The 
biopotential acquisition device may include a biopotential 
amplifier module 127 comprising a biopotential amplifier 
130, an impedance testing circuit 131, a second ground 
switching circuit 129 and a series of inductors 128 operatively 
coupled to conductors extending from the second ground 
Switching circuit 129 and terminating at biopotential acqui 
sition lead connectors 126 and thus operatively coupled to 
biopotential acquisition leads 125 coupled to the connectors 
126. Further provisions may be made for any number of 
biopotential acquisition leads 125, and any number of ground 
leads 120, each lead 125, 120 including a sensor such as a 
surface electrode 122 adapted to be placed on tissues. Further 
provisions may be made for electrical coupling of a biopo 
tential amplifier module 127 to the electrical stimulation 
device 101 through stimulation lead connectors 113, a auxil 
iary power supply connector 114, control I/O connectors 115, 
and auxiliary I/O connectors 16 of the electrical stimulation 
device 101. 
In an exemplary operation, the apparatus of FIG. 14 pro 
vides stimulation from the electrical stimulation device 101 to 
tissues, whereupon a biopotential Voltage is measured by the 
biopotential amplifier 130 operatively coupled to any number 
of biopotential acquisition leads 125 and any number of 
ground leads 120 having electrodes 122 adapted to be placed 
on tissues, the biopotential Voltage including, but not being 
limited to, electroencephalographic (EEG) Voltage, elec 
tromyographic (EMG) Voltage, and electrocardiographic 
Voltage. 
In the apparatus of FIG. 14, an electrical signal for stimu 
lating tissues may be induced using the inductors 128 dis 
posed adjacent the independent conductors extending from 
the second ground Switching circuit 129 and terminating at 
biopotential acquisition lead connectors 126, the electrical 
signal being provided by the electrical stimulation device 
101, and the inductors 128 being electrically coupled to the 
electrical stimulation device 101 at stimulation connectors 
113, whereupon selective control of the electrical signal for 
stimulating tissues is accomplished as previously disclosed 
herein. In other words, the biopotential acquisition device 
includes one or more inductors 128 electrically coupled to the 
electrical stimulation device 101 and operatively coupleable 
one or more respective biopotential acquisition leads 125, the 
electrical stimulation device and inductors being configured 
to selectively deliver tissue stimulation signals through the 
one or more biopotential acquisition leads of the biopotential 
acquisition device. 
In the apparatus of FIG. 14, data transfer of acquired bio 
potential voltage may be provided between the processor 103 
and the biopotential amplifier 130 through any I/O port, such 
as a control I/O connector 15 or an auxiliary I/O connector 
116. In certain embodiments, the biopotential voltage data 
may be used at any time to determine or alter parametric 
values of an electrical signal for stimulating tissues, such as 
via analysis using Software in an external computing device 
102 with subsequent control data being sent from the external 
computing device 102 to a processor 103 in an electrical 
stimulation device 101. In other words, the external comput 
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ing device 102 is configured to determine parametric value of 
an electrical tissue stimulation signal in response to biopo 
tential Voltage data obtained by the biopotential acquisition 
device and to send corresponding control data to the proces 
Sor 103. 
In the apparatus of FIG. 14, the processor 103, for example, 
of the electrical stimulation device 101 may selectively 
sample biopotential Voltage data from the biopotential ampli 
fier 130 of the biopotential acquisition device at times of 
minimal electrical stimulation signal amplitude, preferably 
Zero amplitude, within the period of a high frequency signal 
component of an AMPWM signal. Thus, the biopotential 
acquisition leads 125 may be used for the dual purpose of both 
acquiring biopotential Voltage and delivering an electrical 
signal for stimulating tissues at overlapping, or simultaneous, 
times. The frequencies of a high frequency signal component 
of an AMPWM signal may be selected to be multiples of 
integral powers of two, including but not limited to integral 
multiples of 256 (i.e. 28) such as for example 14,336 hertz 
(256x56) and 16,384 hertz (256x64). Such selection of fre 
quencies facilitates mathematical analysis of acquired biopo 
tential Voltage data. Such mathematical analysis may include 
a FourierTransform analysis whereupon a number of samples 
per second equal to an integral power of two may be pre 
ferred. In the examples of AMPWM signal high frequency 
component frequencies of 14.336 hertz and 16,384 hertz 
given, sampling rates for biopotential Voltage data of 2,048, 
1,024, 512, 256 and 128 samples per second are readily 
achieved within equally spaced intervals of minimal electri 
cal stimulation signal amplitude in the AMPWM signal. 
In the apparatus of FIG. 14, the second ground Switching 
circuit 129 may be operatively coupled to the electrical stimu 
lation device 101 using a control I/O connector 15. Opera 
tionally, the second ground switching circuit 129 receives 
control signals from the processor 103, which allows for 
selective switching of any biopotential acquisition lead 125 to 
an apparatus ground point, permitting advantageous control 
of the biopotential acquisition leads 125 use as either a 
conduction path for an electrical signal for Stimulating tis 
Sues, a conduction path for a biopotential Voltage to the bio 
potential amplifier 130, or a ground. Among other things, 
such selective switching of a biopotential acquisition lead 125 
permits selective use as a reference lead to the biopotential 
amplifier 130 or as a differential lead to the biopotential 
amplifier 130, facilitating differential comparison of biopo 
tential Voltages at more than one acquisition site on a tissue. 
In the apparatus of FIG. 14, an impedance testing circuit 
131 may be included in the biopotential acquisition device 
and operationally coupled to the biopotential amplifier 130. 
The impedance testing circuit 131 may also be coupled to the 
electrical stimulation device 101 using auxiliary I/O connec 
tors 16. In such use, the impedance testing circuit 131 may be 
used to monitor the impedance of tissues in mechanical con 
tact with biopotential acquisition leads 125 and a ground lead 
20, each comprising an electrode 122 adapted to be placed on 
the tissues. Data representing the impedance of tissues is 
transferred to the processor 103 of the electrical stimulation 
device 101 via electrical coupling, for example. The data 
representing impedance of tissues may be used to determine 
or alter parametric values of an electrical signal for stimulat 
ing tissues through, for example, analysis using software in 
the external computing device 102, with subsequent control 
data being sent from the external computing device 102 to the 
processor 103 in the electrical stimulation device 101. 
The data representing impedance of tissues and ongoing 
monitoring for biopotential Voltage integrity, Such as, but not 
limited to, EEG measurement integrity, may be used to deter 
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mine or alter parametric values of an electrical signal for 
stimulating tissues, such as an AMPWM signal. 
The use of methods to monitor for biopotential voltage 
integrity accomplishes various means of guiding a user and 
assuring improved biopotential signal data throughout an 
acquisition time period. For example, the apparatus may 
include an alert for notifying a user if integrity is lost during 
treatment. Such alert may be provided, for example, via soft 
ware analysis in an external computing device 102. In another 
embodiment, such alert may be sent to a remote indicator 
Such as a pager worn by a user. Further, the apparatus may 
include various means of indicating to a user when good 
biopotential Voltage integrity is achieved as biopotential 
acquisition leads 125 and ground leads 120 are first being 
applied to tissues, prior to the acquisition of data. Such indi 
cators may be provided, for example, via graphic user inter 
face Software in an external computing device 102 or via any 
number of hardware indication means. 
With reference to FIG. 15, another embodiment of a tissue 
stimulation apparatus for providing an electrical tissue stimu 
lation signal that reduces tissue impedance and increases 
depth of signal penetration is shown as comprising an elec 
trical stimulation device 101 and an adjunct electrical stimu 
lation apparatus 132 to be used with an independent biopo 
tential Voltage measurement apparatus, Such as, but not 
limited to, an EEG measurement apparatus 137. Under nor 
mal operating conditions, an EEG measurement apparatus 
137 is typically used only for the purposes of acquiring EEG 
Voltage data and for providing Such data to an external com 
puting device 102 through any data cable 138 or other cou 
pling capable of sufficiently transferring the data. Acquisition 
of the EEG voltage is normally accomplished through any 
number of leads electrically coupled to an EEG measurement 
apparatus 137 at an interface 139, for example. Such number 
of leads may include an EEG sensor set 136 comprising, but 
not being limited to, a series of conductors, a series of elec 
trodes and features for positioning the electrodes, such as via 
integration of Such sensors in a cap adapted to be worn by a 
Subject. In other words, the tissue stimulation apparatus may 
comprise a sensor set 136, an independent biopotential Volt 
age measurement apparatus 137, and an adjunct electrical 
stimulation apparatus 132 operatively connected between the 
sensor set 136 and the independent biopotential voltage mea 
Surement apparatus. The independent biopotential Voltage 
measurement apparatus 137 may be operatively coupled to 
the electrical stimulation device 101, and may be configured 
to transmit through stimulation connectors 113 to the sensor 
set, electrical tissue stimulation signals received from the 
electrical stimulation device 101, to transmit biopotential 
voltage from the sensor set 136 to the independent biopoten 
tial Voltage measurement apparatus 137, and to receive con 
trol signals from the processor 103 of the electrical stimula 
tion device 101 through control I/O connectors 115, 
The exemplary apparatus illustrated in FIG. 15 enables use 
of an independent biopotential Voltage measurement appara 
tus. Such as, but not limited to, an EEG measurement appa 
ratus 137, within an apparatus for providing an electrical 
signal for stimulating tissues. This use may be accomplished 
by placing an adjunct electrical stimulation apparatus 132 
operatively between an EEG sensor set 136 and an EEG 
measurement apparatus 137. The adjunct electrical stimula 
tion apparatus 132 may include an adjunct Switching control 
135 operatively coupled to a processor 103 of an electrical 
stimulation device 101 using control I/O connectors 115. The 
adjunct electrical stimulation apparatus may also include a 
series of EEG lead conductors 142 and matched transfer 
conductors 140, for example, along with a series of adjunct 
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switching circuits 133 operatively coupled to the adjunct 
switching control 135 via switching control conductors 141, 
and further operatively coupled to stimulation connectors 113 
of the electrical stimulation device 101. 
In operation, the apparatus of FIG. 15 provides for an 
adjunct electrical stimulation apparatus 132 operatively 
coupled to an electrical stimulation device 101 to both receive 
electrical signals through stimulation connectors 113 for 
stimulating tissues and to transfer control signals to a proces 
sor 103 through control I/O connectors 115. The adjunct 
electrical stimulation apparatus 132 may be further opera 
tively coupled to an EEG sensor set 136 at a cable interface 
connector 134 for receiving EEG voltage. The adjunct elec 
trical stimulation apparatus 132 may be further operatively 
coupled to an EEG measurement apparatus 137 at an interface 
139 such as the same connecting features provided by an EEG 
sensor set 136. 
With reference to FIGS. 15 and 16, a series of adjunct 
Switching circuits 133 may be provided, each comprising any 
substantial circuit for switching 143, for example, that pro 
vides a selectable conduction pathway for an EEG lead con 
ductor 142 between (a) an electrical signal for stimulating 
tissues, such as provided by an electrical stimulation device 
101 through electrical coupling at stimulation connectors 
113, (b) a transfer conductor 140 terminated at an interface 
139 and further provided to an independent EEG measure 
ment apparatus 137, or (c) a ground. Further provision made 
in the adjunct Switching circuit 133 may include Switching 
control conductors 141 electrically coupled to an adjunct 
switching circuit 135, which may be used, for example, to 
determine the state of the adjunct switching circuit 133 and 
therefore the conduction path provided to the EEG lead con 
ductor 142. 
As shown in FIG. 15, the electrical stimulation device 101 
may be combined with an adjunct electrical stimulation appa 
ratus 132 and biopotential Voltage measurement apparatus, 
such as an EEG measurement apparatus 137. At times, for 
example, when a biopotential Voltage measurement is 
required, biopotential voltage from a particular EEG lead 
conductor 142 may be directed to a transfer conductor 140 by 
selective Switching via an adjunct Switching control 135 oper 
ated by the processor 103 in the electrical stimulation device 
101. Alternately, at times, such as when an electrical signal 
for stimulating tissues is required, the signal may be directed 
from a stimulation connector 113 to a particular EEG lead 
conductor 142 by selective Switching from an adjunct Switch 
ing control 135 operated by the processor 103 in the electrical 
stimulation device 101. Alternately, at times, such as when a 
particular EEG lead conductor 142 is to be grounded, selec 
tive switching from an adjunct switching control 135 oper 
ated by the processor 103 in the electrical stimulation device 
101 may be used to electrically couple the EEG lead conduc 
tor 142 to ground. In other words, the processor 103 of the 
electrical stimulation device 101 and the adjunct switching 
control may direct biopotential Voltage from selected elec 
trodes of the sensor set 136 to the biopotential measurement 
apparatus 137 by selective switching via the adjunct switch 
ing control 135 operated by the processor 103 when a biopo 
tential Voltage measurement is required, may direct tissue 
stimulation signals from the electrical stimulation device101 
through selected Stimulation connectors 113 to correspond 
ing electrodes of the sensor set 136 through respective EEG 
lead conductors 142 by selective switching via the adjunct 
switching control 135 operated by the processor 103 when 
tissue stimulation is required, and may couple selected elec 
trodes of the sensor set 136 to ground by selective switching 
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via the adjunct switching control 135 operated by the proces 
sor 103 when grounding of an electrode is required. 
As shown in FIG. 14, inductors 128 and a second ground 
switching circuit 129 of the apparatus of FIG. 14 may be 
replaced, for example, by an adjunct Switching circuit 133 
and an adjunct switching control 135 to control the use of 
individual leads. In other words, the biopotential acquisition 
device of FIG. 14 may be modified to include at least one 
adjunct Switching circuit 133 and an adjunct Switching con 
trol 135 electrically coupled to the electrical stimulation 
device 101, with the adjunct switching circuit 133 being 
operatively coupled to at least one biopotential acquisition 
lead 125, the electrical stimulation device 101 and an adjunct 
switching control 135 selectively connecting the electrical 
stimulation device 101 to selected leads to transmit tissue 
stimulation signals to the selected leads and connecting 
selected leads to the biopotential amplifier 130 to transmit 
biopotential voltages to the biopotential amplifier 130. 
Accordingly, as shown in FIG. 17, the tissue stimulation 
apparatus may comprise an electrical stimulation device 101 
and a biopotential amplifier and switching module 155, and 
the module may further comprise a biopotential amplifier 
130, an impedance testing circuit 131, a series of EEG lead 
conductors 142 operatively coupled to conductors terminat 
ing at biopotential acquisition lead connectors 126, matched 
transfer conductors 140, a series of adjunct Switching circuits 
133 operatively coupled to the adjunct switching control 135 
via switching control conductors 141, and further operatively 
coupled to stimulation connectors 113 of an electrical stimu 
lation device 101. Further provisions may be made for any 
number of biopotential acquisition leads 125, and any number 
of ground leads 120, and a mechanism that may be used with 
the leads to provide for electrodes 122 adapted to be placed on 
tissues. Further provisions may be made for electrical cou 
pling of a biopotential amplifier and switching module 155 to 
the electrical stimulation device 101 through stimulation con 
nectors 113, auxiliary power supply 14, control I/O connec 
tors 115 and auxiliary I/O connectors 16. 
In an exemplary operation, the apparatus of FIG. 17 pro 
vides stimulation from the electrical stimulation device 101 to 
tissues, whereupon a biopotential Voltage may be measured 
by a biopotential amplifier 130 operatively coupled through 
an adjunct switching circuit 133, transfer conductor 140 and 
EEG lead conductor 142 to any number of biopotential acqui 
sition leads 125, any number of ground leads 120 and the 
electrode 122 adapted to be placed on tissues. The biopoten 
tial Voltage may include, but is not limited to including, 
electroencephalographic (EEG) Voltage, electromyographic 
(EMG) Voltage, and/or electrocardiographic Voltage. 
As shown in FIG. 17, an electrical signal for stimulating 
tissues may be electrically coupled to any number of biopo 
tential acquisition leads 125, any number of ground leads 120 
and the electrode 122 adapted to be placed on tissues, the 
electrical signal being provided by the electrical stimulation 
device 101, through an adjunct switching circuit 133, transfer 
conductor 140 and EEG lead conductor 142, where the 
adjunct Switching circuit 133 is operatively coupled to an 
adjunct Switching control 135 via Switching control conduc 
tors 141, and further operatively coupled to stimulation con 
nectors 113 of the electrical stimulation device 101, where 
upon selective control of the electrical signal for stimulating 
tissues may be accomplished as previously disclosed herein. 
Further, and with particular reference to FIG. 18, the 
adjunct Switching circuit 133 and an adjunct Switching con 
trol 135 of the apparatus of FIG. 15 may be replaced by 
inductors 128 and a second ground Switching circuit 129, as 
taught in FIG. 14 to control the use of individual leads. In 
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other words, the adjunct electrical stimulation apparatus 132 
may be modified to include a ground switching circuit 129 
operatively coupled to the processor 103 of the electrical 
stimulation device 101, to the biopotential amplifier 130, and 
by conduction paths to respective electrodes of the sensorset, 
a plurality of inductors 128 operatively coupled to the elec 
trical stimulation device 101 and to the conduction paths, and 
the processor and ground Switching circuit may be configured 
to provide selectable conduction pathways for tissue stimu 
lation signals between the electrical stimulation device 101 
and the electrodes of the sensor set, and for biopotential 
voltages between the electrodes of the sensor set and the 
biopotential Voltage measurement apparatus 137. 
Accordingly, as shown in FIG. 18, as the tissue stimulation 
apparatus may comprise a basic electrical stimulation appa 
ratus 1 and an adjunct electrical induction and Switching 
apparatus 156 to be used with an independent biopotential 
Voltage measurement apparatus, such as, but not limited to, an 
EEG measurement apparatus 137. Under normal operating 
conditions, an EEG measurement apparatus 137 is typically 
utilized only for the purposes of acquiring EEG voltage data 
and for providing Such data to an external computing device 
102 through any data cable 138 or other coupling capable of 
sufficiently transferring the data. Acquisition of the EEG 
Voltage may be accomplished through any number of leads 
electrically coupled to an EEG measurement apparatus 137 at 
an interface 139, for example. Such number of leads may 
include an EEG sensor set 136 comprising, but not being 
limited to, a series of conductors, a series of electrodes and 
features for positioning the electrodes, such as a cap adapted 
to be worn by a user and into which the electrodes may be 
integrated. 
The exemplary apparatus illustrated in FIG. 18 enables use 
of an independent biopotential Voltage measurement appara 
tus. Such as, but not limited to, an EEG measurement appa 
ratus 137, within the tissue stimulation apparatus. This use 
may be accomplished by placing an adjunct electrical induc 
tion and Switching apparatus 156 operatively between an 
EEG sensorset 136 and an EEG measurement apparatus 137, 
whereupon said adjunct electrical induction and Switching 
apparatus 156 comprises a second ground Switching circuit 
129 operatively coupled to any number of transfer conductors 
140 and EEG lead conductors 142. In the system of FIG. 18, 
a second ground Switching circuit 129 may be further opera 
tively coupled to an electrical stimulation device 101 using a 
control I/O connector 15. Operationally, the second ground 
Switching circuit 129 receives control signals from a proces 
sor 103, which allows for selective switching of any EEG lead 
conductor 142 to a system ground point, permitting advanta 
geous control of the EEG lead conductor's 142 use as either a 
conduction path for an electrical signal for Stimulating tis 
Sues, or a conduction path for an EEG measurementapparatus 
137, or a ground. Further provisions may be made for elec 
trical coupling of an adjunct electrical induction and Switch 
ing apparatus 156 to a basic electrical stimulation apparatus 1 
through stimulation connectors 113, auxiliary power Supply 
14, control I/O connectors 115 and auxiliary I/O connectors 
16. 
In operation, the apparatus of FIG. 18 provides for an 
adjunct electrical induction and Switching apparatus 156 
operatively coupled to the electrical stimulation device 101 to 
both receive electrical signals through stimulation connectors 
113 for stimulating tissues and to transfer control signals 
between a processor 103 and a second ground Switching 
circuit 129 through control I/O connectors 115. The adjunct 
electrical induction and switching apparatus 156 may further 
be operatively coupled to an EEG sensor set 136 at a cable 
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interface connector 134 for receiving EEG voltage. The 
adjunct electrical stimulation apparatus 132 may further be 
operatively coupled to an EEG measurement apparatus 137 at 
an interface 139 Such as the same connecting features pro 
vided by an EEG sensor set 136. 
With reference to FIG. 19, another embodiment of a tissue 
stimulation apparatus 144 for providing an electrical signal 
for stimulating tissues comprises an electrical stimulation 
device 101, may comprise an external computing device 102. 
and comprises one or more circuits adapted to provide elec 
trical stimulation signals from the electrical stimulation 
device to tissues of a Subject in accordance with features and 
operations of the embodiments, or Substantial equivalents, 
such as are illustrated in FIGS. 12-18 and taught herein. With 
further reference to FIG. 19, the tissue stimulation apparatus 
144 for providing an electrical signal for stimulating tissues 
may include a mobile apparatus 146 Such as a wheeled cart or 
a wheeled Stand for transportability, and a material Supplies 
storage and use apparatus 147 that carries consumable Sup 
plies for use in administering tissue stimulation signals to a 
Subject. 
In operation, the tissue stimulation apparatus 144 of FIG. 
19 provides a mobile system for providing an electrical signal 
for stimulating tissues, wherein the mobile apparatus 146 
facilitates movement of the tissue stimulation apparatus 144 
to a subject, and wherein a tissue stimulation apparatus 144 
may provide stimulation through composite stimulation leads 
145. Such composite stimulation leads 145 comprising any 
combination of stimulation leads 121, ground leads 120, and/ 
or external stimulation device cables 124. 
In the tissue stimulation apparatus 144 shown in FIG. 19, a 
number of consumable supplies may be used with the tissue 
stimulation apparatus to provide an electrical signal for 
stimulating tissues, the Supplies including, but not being lim 
ited to conductive pastes, conductive gels, cleaning materials, 
Such as cotton or gauze, cleaning agents, such as rubbing 
alcohol, and/or any number of Supporting materials. In the 
tissue stimulation apparatus 144 of FIG. 19, the material 
Supplies storage and use apparatus 147 may be operatively 
coupled to or carried by the mobile apparatus 146, for 
example, to enable presenting the consumable Supplies dur 
ing use and storing the consumable Supplies during non-use. 
Specifically, the material Supplies storage and use apparatus 
147 may comprise, for example, a plurality of receptacles and 
storage features, including, but not limited to, a waste storage 
receptacle 148, a conductive gel receptacle 149, a conductive 
paste receptacle 150, a cleaning materials receptacle 151, an 
alcohol receptacle 152, any number of other Supporting mate 
rials receptacles 153, and/or an electrode storage receptacle 
154. 
In the tissue stimulation apparatus 144 shown in FIG. 19. 
provisions may be made for any method of sensing the quan 
tities of materials stored in receptacles such as, but not limited 
to, the waste storage receptacle 148, the conductive gel recep 
tacle 149, the conductive paste receptacle 150, the cleaning 
materials receptacle 151, the alcohol receptacle 152, and/or 
any further number of supporting materials receptacles 153. 
The method is further realized using any Suitable computing 
device 102 integral to operate with the composite electrical 
stimulation apparatus 144 to acquire signals from sensors 60 
using software to manage inventory. In other words, the tissue 
stimulation apparatus 144 may include one or more sensors 
60 carried by the material supplies and use apparatus 147 and 
configured to sense the quantities of materials stored in recep 
tacles of the material Supplies storage and use apparatus 147. 
The tissue stimulation apparatus 144 may include a comput 
ing device 102 coupled to the one or more sensors and con 
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figured to manage inventory in response to signals acquired 
from the one or more sensors. The method may further 
include use of, for example, various alerts when inventory of 
any material reaches a predetermined low point. In other 
words, the tissue stimulation apparatus 144 may be config 
ured to generate an alert when inventory of any material 
reaches a predetermined low point. The method may further 
include interfacing, such as via Software, to provide orders to 
replenish material inventory when a pre-determined low 
point is reached. In other words, the tissue stimulation appa 
ratus 144 may be configured to order materials necessary to 
replenish inventory when a pre-determined low point is 
reached. The method may further provide for interfacing with 
a network, Such as the Internet 62, and to enable ordering by 
a remote Supply entity for the purposes of replenishing mate 
rial inventory when a pre-determined low point is reached. In 
other words, the tissue stimulation apparatus 144 may be 
configured to order materials by interfacing with a commu 
nications network Such as the internet 62. 
In the tissue stimulation apparatus 144 shown in FIG. 13, 
the electrode storage receptacle 154 may be configured to 
provide storage for electrodes 122 for leads, the electrodes 
made of for example, photosensitive materials, such as sil 
Ver-silver/chloride. In practice, the electrode storage recep 
tacle 154 allows the electrodes 122 to be covered so as to 
block access of ambient light during periods of non-use. 
In tissue stimulation apparatus Such as those shown in a 
number of the figures, the use of leads may be dynamically 
altered between (a) conducting biopotential Voltages, (b) con 
ducting an electrical signal for stimulating tissues and (c) a 
ground, in conjunction with the use of computational analysis 
of the acquired data, Such as biopotential data, providing 
indication of a region of tissue to be stimulated. Based on Such 
analysis, Sufficient leads may be identified and appropriately 
placed so as to provide a number of possible conduction paths 
passing in near proximity to the region of tissue of interest. 
Then, control signals from a processor 103 of an electrical 
stimulation device 101 may be used to selectively switch use 
of the leads, in accordance with methods taught herein, to 
provide any number of dynamically controlled conductors 
and grounds for an electrical signal for stimulating tissues. 
The electrical stimulation device 101 may then be used to 
deliver the electrical signal to the appropriate region of tissues 
and may further be used to assess Subsequently acquired data 
for the purpose of Subsequent altering of lead use. In other 
words, tissues of a subject may be stimulated by first provid 
ing a tissue stimulation apparatus configured to dynamically 
alter the use of leads between conducting biopotential volt 
ages, conducting an electrical signal for stimulating tissues, 
and grounding, in response to a computational analysis of 
biopotential data acquired from a region of tissue to be stimu 
lated, acquiring biopotential data from a region of tissue to be 
stimulated, performing a computational analysis of the 
acquired biopotential data, in response to the analysis, iden 
tifying and placing Sufficient leads so as to provide a number 
of possible conduction paths passing in near proximity to a 
region of tissue of interest, and dynamically controlling elec 
trical signal delivery to the region of tissue of interest by 
selectively switching the use of the leads as conductors and 
grounds. In addition Subsequently acquired data may be 
assessed for the purpose of Subsequent altering of lead use. 
In place of a battery 108 any one of a number of circuit 
embodiments known in the art may be used to provide elec 
trical isolation from an external power source 105 and may 
further be used to provide isolated electrical power to one or 
more circuits of the electrical stimulation device 101. 
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In embodiments of the present invention, an external com 
puting device 102 may functionally interface with other net 
work computing devices, including but not limited to com 
puting devices coupled to or otherwise accessible via the 
Internet. Such interfaces to other network computing devices 
may be used, for example, to facilitate the determination or 
alteration of parametric values of an electrical signal for 
stimulating tissues through analysis using software in a net 
work computing device, with Subsequent control data being 
sent from the network computing device via the functional 
interfaces to an external computing device 102, further opera 
tionally coupled to a processor 103 in an electrical stimula 
tion device 101. In other words, the external computing 
device 102 may be configured to functionally interface with at 
least one other network computing device to determine para 
metric values of an electrical tissue stimulation signal; and to 
receive Subsequent corresponding control data from the other 
network computing device via the functional interfaces. The 
external computing device 102 may be configured to func 
tionally interface with the other network computing device 
via the Internet. 
In embodiments of the present invention, the time-aver 
aged current flow of an electric signal for stimulating tissues 
may be varied by modifying the duty cycle of the high fre 
quency component of an AMPWM signal. This method of 
varying the time-averaged current flow may include varying 
stimulation intensity provided to a Subject by an external 
stimulation device 123 such as, but not limited to, the light 
intensity of an optical stimulation device, the magnetic field 
strength of an electromagnetic device, the mechanical action 
of an electromechanical stimulation device or the Sound 
intensity of an audio stimulation device. 
In embodiments of the present invention, the apparatus for 
providing electrical signals for stimulating tissues may be 
integrated with other instruments used during periods of 
therapy. For example, such instruments may be electrically 
coupled to an electrical stimulation device 101 through aux 
iliary I/O connectors 16. In other words, the tissue stimulation 
apparatus may include data collection instruments configured 
to collect data on a Subject during periods of therapy and 
electrically coupled to the electrical stimulation device 101. 
Among other things, this approach allows simultaneous col 
lection of instrument data during periods of therapy. 
Embodiments of the present invention may include the use 
of a software program to execute various means of identifying 
a Subject. Such means may include, but are not limited to, 
electronic or magnetic identification media. Such means may 
also include, but are not limited to, the use of digital photo 
graphs of a subject to both aid in identification of the subject 
and to provide visual Support to aid in proper location for the 
placement of any leads associated with the apparatus. 
Software may also be used to facilitate the playing of music 
through an external stimulation device 123 for the subject 
during therapy, with the music being chosen, for example, to 
enhance therapeutic effect. 
Software may also be used to facilitate the playing of 
educational audio or video media clips for the Subject at any 
time associated with therapy, with the media clips being cho 
sen, for example, to enhance therapeutic effect. 
A number of methods have been described for deriving 
quantities such as the frequency, phase, pulse width duty 
cycle, and amplitude of electrical signals for stimulating tis 
Sues, e.g., signals such as AMPWM signals, that reduce tissue 
impedance and increase depth of signal penetration. Such 
derivations are anticipated through either manual means Such 
as those performed by a human, or automatic means such as 
those performed by computational methods in software, or by 
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any combination of both means. In various methods taught 
herein, the term “frequency” refers to any singular value or to 
any range of values that change over a period of time during 
therapeutic activity (e.g. a “frequency Sweep'). 
Such signals may be used to stimulate brain tissue. Accord 
ing to one method of electrically stimulating tissue, paramet 
ric values of an electrical tissue stimulation signal are deter 
mined in response to biopotential Voltage data obtained from 
a region of tissue to be stimulated. An electrical stimulation 
signal having the determined parametric values is then gen 
erated and applied to the region of tissue. One exemplary way 
of determining parametric signal values includes first taking a 
measure of the EEG activity of at least a portion of the brain, 
or the EEG of the entire brain, of a subject prior to the 
generation and application of any electrical signal for the 
purposes of stimulating brain tissues. Upon collection of EEG 
activity from the brain for a sufficient period of time, the EEG 
data is analyzed for any number of relationships. A sufficient 
period of time for collecting EEG activity may be between, 
for example, one second and one hour. The relationships for 
which the EEG data is analyzed may include, but are not 
limited to, the amount of measured Voltage in single fre 
quency components; in composites of multiple frequencies, 
also known as frequency bands; and/or in frequency band 
ratios, for the cases of both individual EEG sites and for 
multiple EEG sites. These relationships may further include, 
but are not limited to, various statistical analyses involving 
measured EEG voltages and their frequency and phase com 
ponents, taken at both individual EEG sites and for multiple 
EEG sites. These statistical analyses may include, but are not 
limited to, measures of variance, correlation, and/or coher 
ence. These relationships may further include, but are not 
limited to, various analyses that provide indication of the 
spatial origin and/or source localization of the measured 
EEG, such as that accomplished by performing “inverse 
EEG' analysis. 
Parametric determination may further rely on making com 
parisons between the findings of the EEG analysis and similar 
measures known to represent normal brain activity in a 
healthy normal population of living beings such as human 
beings. Such a comparison may be performed, for example, 
for the purpose of quantifying differences between the mea 
sured EEG of a subject and the EEG expected in normal brain 
activity. Such differences are used to identify particular brain 
sites or regions where frequency and amplitude components 
of the subject's EEG are either excessive; that is, where they 
exhibit greater values than normal; diminished; that is, where 
they exhibit values lower than normal; or highly variable; that 
is, where they exhibit values that fluctuate more than normal. 
As shown in FIG. 22, parametric determination may 
include selecting quantities Such as the frequency, amplitude, 
and phase components of the low frequency component of an 
AMPWM signal based on such comparisons in an attempt to 
achieve normal EEG presentation. By using pulse width 
modulation for the purpose of varying the duty cycle of the 
electrical signal of relatively high frequency, the time-aver 
aged current deliverable by that signal can be controlled. 
Therefore, further to this embodiment, the pulse width duty 
cycle of the high frequency component of an AMPWM signal 
is selected based on Such comparisons to affect the time 
averaged current delivered by the AMPWM signal in an 
attempt to achieve normal EEG presentation. 
In one embodiment of this method of parametric determi 
nation, the frequencies for the low frequency signal compo 
nents of the electrical signal, such as an AMPWM signal, are 
selected to modulate either excessive or diminished EEG 
activity, as determined by the aforementioned comparative 
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analysis. In other words, determining parametric values may 
include selecting frequencies for low frequency signal com 
ponents of an electrical tissue stimulation signal to modulate 
either excessive or diminished EEG activity, as determined by 
the comparative analysis. In this embodiment, if excessively 
high frequency EEG activity were found in a region of the 
brain, a lower frequency may be used as the low frequency 
component of the electrical signal for stimulating that region 
of the brain. In other words, selecting frequencies for low 
frequency signal components may include selecting a lower 
frequency as the low frequency component of the electrical 
signal for stimulating a region of the brain where excessively 
high frequency EEG activity is found, with a “lower fre 
quency' being defined as between 1 and 20 hertz lower than 
the value of the identified excessively high EEG frequency. In 
practice, a progressively lower frequency might be used in 
therapeutic activity until the excessive EEG activity in a 
region of the brain reduces to a more normal level. In one 
embodiment of the invention, the EEG of the brain can be 
continually monitored during therapeutic activity, providing 
an indication of the effectiveness of the therapeutic activity. 
In embodiments of the present invention electrical stimu 
lation signals such as AMPWM signals may be directed 
through desired tissues or tissue regions by introducing Such 
signals so as to cause current to flow through the desired 
tissues or tissue regions. As shown in FIG. 24, this may be 
accomplished by first placing any number of stimulating 
leads 121 in proximity to the tissues or tissue regions to be 
stimulated, and further placing any number of ground leads 
120 in another proximity to the tissues or tissue regions to be 
stimulated such that a vector path extends between stimulat 
ing leads and ground leads and passes through the particular 
tissues meant to receive electrical stimulation. In other words, 
at least one stimulating lead 121 and one ground lead 20 are 
placed in proximity to a tissue region to be stimulated Such 
that a vector path extending between the stimulating lead and 
the ground lead passes through the tissue region to be stimu 
lated. An electrical stimulation signal is then introduced 
through the at least one stimulating lead such that current is 
caused to flow along the vector path through the tissue region 
between the stimulating lead and the ground lead. 
Thus, any number of stimulating leads may, for example, 
be placed in proximity to the brain tissues where abnormal 
EEG activity has been determined to exist. Further, any 
appropriate number of ground leads may be placed in further 
proximity to the brain tissues so as to create a vector that 
extends between stimulating leads and ground leads and that 
passes through the brain tissue to be stimulated. In this 
arrangement, application of an electrical signal for stimulat 
ing brain tissues will cause a current flow through Such brain 
tissue, in an approximate vector direction between stimulat 
ing leads and ground leads. 
In another embodiment of parametric determination for the 
purpose of stimulating a brain, a plurality of desirable stimu 
lation frequencies may be determined by EEG analysis as 
detailed above. As previously taught, a form of an AMPWM 
signal may be generated by, for example, creating a low 
frequency component waveform featuring multiple fre 
quency components, as determined by inverse Fourier Trans 
form methods. The plurality of desirable stimulation frequen 
cies may be used to determine a single waveform of multiple 
low frequency components by inverse Fourier Transform 
computation, and may be used for creating an AMPWM 
signal and may further be used for stimulating a brain, as 
previously described. In other words, the application of 
inverse Fourier Transform methods may include using 
inverse Fourier Transform computation to determine from the 
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plurality of desirable stimulation frequencies a single wave 
form of multiple low frequency components, and the appli 
cation of an electrical stimulation signal may include using 
the single waveform to create and use an AMPWM signal to 
stimulate brain tissue 
In another embodiment of parametric determination for the 
purpose of stimulating a brain, EEG data from brain tissue 
may further be acquired during therapeutic tissue stimulation 
signal application activity and analyzed at a time generally 
concurrent to the stimulation signal being applied. In other 
words, obtaining biopotential Voltage data may include 
acquiring EEG data of brain tissue during therapeutic stimu 
lation signal application activity, and determining parametric 
values may include analyzing the EEG data as the stimulation 
signal is being applied. Analysis of the EEG may include the 
use of one or more of those methods previously described for 
EEG acquired from brain tissue prior to stimulating the brain, 
for example. Based on this analysis, comparisons may be 
made between the acquired EEG presentation and a desired 
EEG in a normal presentation. In this alternate embodiment, 
quantities such as the frequency, amplitude and phase com 
ponents of the low frequency component of an AMPWM 
signal may be altered based on these comparisons in an 
attempt to achieve a normal EEG presentation. In this imple 
mentation, the pulse width duty cycle of the high frequency 
component of an AMPWM signal may be altered based on the 
comparisons to affect the time averaged current delivered by 
the AMPWM signal in an attempt to achieve normal EEG 
presentation. 
In yet another embodiment of parametric determination for 
the purpose of stimulating a brain, any number of sensory 
inputs other than EEG data may be substituted in the methods 
described herein to enable quantifying of the condition of 
tissues or any other functional state of a Subject. In other 
words, determining parametric values may include obtaining 
sensory inputs quantifying the functional state of a subject, 
and then determining parametric values for the purpose of 
stimulating brain tissue in response to the sensory inputs. 
Such sensory inputs may include, but are not limited to, tissue 
impedance, temperature, oxygen Saturation, EMG activity, 
electrocardiographic activity, biochemical levels, and/or 
measures involving respiration patterns. 
Further to the methods disclosed for deriving quantities 
Such as the frequency, phase, pulse width duty cycle, and 
amplitude of electrical signals for stimulating tissues, such as 
an AMPWM signal, a number of methods may be used for 
controlling the application time of the signals. 
For example, the amount of time that an electrical signal for 
stimulating tissues is to be applied to a Subject may be pre 
determined and set programmatically based on empirical evi 
dence gained from clinical experience, and then controlled by 
Software to start and stop the application of the signal. 
Alternatively, software may be provided to start an electri 
cal signal for stimulating tissues and to stop the signal appli 
cation automatically, as certain measures in tissue electrical 
properties are achieved. In other words, controlling signal 
application time may include starting and then automatically 
stopping an electrical tissue stimulation signal in response to 
the achievement of certain desired measures of tissue electri 
cal properties. With reference to the method of stimulating 
brain tissues taught herein, the EEG of the brain may be 
further acquired during the therapeutic activity and analyzed 
at a time generally concurrent with the stimulation signal 
being applied. The electrical signal application may be 
stopped when any number of predetermined EEG properties 
is achieved. In other words, controlling signal application 
time may include acquiring EEG data from brain tissue dur 
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ing therapeutic electrical tissue stimulation activity, analyZ 
ing the acquired EEG data as the stimulation signal is being 
applied, and stopping the electrical signal application when 
one or more predetermined EEG properties are achieved. This 
alternative method may include termination of signal appli 
cation in response to one or more other measures of sensory 
input including, but not limited to, tissue impedance, tem 
perature, oxygen Saturation, EMG activity, electrocardio 
graphic activity, biochemical levels, and measures involving 
respiration patterns. 
Alternatively, and as shown in FIG. 21, automation of 
signal termination based on sensory input may be combined 
with predetermination of a time for signal application, Such 
that the electrical signal will not exceed a predetermined time 
if desired electrical properties of the tissue are not achieved. 
Generally, each of the methods disclosed can be applied to 
tissues that are not brain tissues. Such as tissues including, but 
not limited to, muscles, bones, tendons, ligaments, cartilage, 
fascia, dermis (i.e., layers of skin), and/or internal organs. 
Parametric determination generally relies on first taking mea 
Sures of tissue electrical properties prior to application of any 
electrical signal for the purposes of stimulating the tissues. 
Upon collection of tissue electrical property data, an analysis 
for the purpose of making statistical comparisons between the 
findings and measures known to represent normal tissue elec 
trical properties in a healthy normal population of living 
beings, including human beings, may be performed. In other 
words, a method is provided for electrically stimulating tissue 
in which parametric values of an electrical tissue stimulation 
signal may be determined by first taking measures of electri 
cal properties of a region of tissue to be stimulated, making 
statistical comparisons between the measures and measures 
known to represent normal tissue electrical properties in a 
healthy normal population of living beings, determining para 
metric values of an electrical tissue stimulation signal in 
response to the comparisons, and then generating and apply 
ing to the region of tissue an electrical stimulation signal 
having the determined parametric values. 
In embodiments of the present invention, the method of 
parametric determination is completed as quantities such as 
the frequency, amplitude and phase components of the low 
frequency component of an AMPWM signal are selected 
based on Such comparisons, in an attempt to achieve normal 
tissue electrical property presentation. By using pulse width 
modulation for the purpose of varying the duty cycle of a high 
frequency component of an AMPWM signal, the time-aver 
aged current deliverable by that signal can be controlled. 
Thus, the pulse width duty cycle of the high frequency com 
ponent of an AMPWM signal may be selected, based on these 
comparisons, to affect the time averaged current delivered by 
the AMPWM signal, in an attempt to achieve normal tissue 
electrical property presentation. 
As described further above, in directing the electrical sig 
nals for the purpose of stimulating tissues, in embodiments of 
the present invention, the electrical signal may be introduced 
So as to cause current to flow through Such tissues, involving 
first placement of any number of stimulating leads 121 in 
proximity to the tissues, and further by placing any Suitable 
number of ground leads 120 in another proximity to the 
tissues. In one placement pattern, a vector direction between 
stimulating leads 121 and ground leads 120 passes through 
the particular tissues meant to receive electrical stimulation. 
Thus, stimulation of tissues other than a brain may be 
accomplished by placing any appropriate number of stimu 
lating leads 121 in proximity to the tissues. Correspondingly, 
any suitable number of ground leads 120 are placed in further 
proximity to the tissues, so as to create a vector direction 
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between stimulating leads 121 and ground leads 120 that 
passes through the particular tissue to be stimulated. In this 
arrangement, application of an electrical signal for stimulat 
ing tissues will cause a current flow through the tissues, in an 
approximate vector orientation between electrodes 122 of 
stimulating leads 121 and ground leads 120. 
In yet another embodiment of parametric determination for 
the purpose of using electrical signals for stimulating tissues, 
including brain tissues and tissues that are not brain tissues, a 
measure of biochemicals, particularly neurochemicals and 
neurotransmitters, may first be taken from tissues and/or flu 
ids relevant to the tissues to be stimulated. The measures are 
then analyzed by, for example, making comparisons between 
the findings of the measure of biochemicals and similar mea 
sures known to represent normal levels of the biochemicals in 
a healthy normal population of living beings, including 
human beings. Such comparisons may be done for the pur 
pose of quantifying differences that indicate either excessive, 
that is, greater amounts of certain biochemicals than normal, 
or diminished, that is, lower amounts of certain biochemicals 
than normal. In other words, a method is provided that may 
include determining parametric values of an electrical tissue 
stimulation signal by taking measures of biochemicals from 
tissues and/or fluids relevant to the tissues to be stimulated, 
analyzing the measures, and determining parametric values 
of an electrical tissue stimulation signal in accordance with 
the analysis of the measures. An electrical stimulation signal 
may then be generated and applied to the region. The applied 
signal may have the determined parametric values and may be 
configured to reduce tissue impedance and increase depth of 
signal penetration. 
As shown in FIG. 23, an embodiment of parametric deter 
mination may further include determination of molecular 
resonant frequencies associated with biochemicals deter 
mined to be excessive or diminished in a subject. In this 
embodiment, an electrical signal for stimulating tissues may 
be applied for the purpose of affecting abnormal biochemical 
levels. In other words, determining parametric values in 
response to the comparisons may include determining elec 
trical signal parameters that will tend to normalize abnormal 
biochemical levels when Such a signal is generated and 
applied to the Subject. 
Parametric determination, in these embodiments, may 
include selecting quantities Such as the frequency, amplitude, 
and/or phase components of the low frequency component of 
an AMPWM signal, based on the molecular resonant frequen 
cies associated with biochemicals to be used, in an attempt to 
achieve normal biochemical presentation. The pulse width 
duty cycle of the high frequency component of an AMPWM 
signal may be selected based on Such comparisons, to affect 
time averaged current delivered by the AMPWM signal, in an 
attempt to achieve normal biochemical presentation. In one 
embodiment of the invention, the involved biochemical levels 
can be continually or periodically monitored during therapeu 
tic activity, providing an indication of the effectiveness of the 
therapeutic activity. 
In yet another embodiment of parametric determination 
that relies on making comparisons between the findings of 
abnormal biochemical levels in a subject, the determination 
of the frequencies for the low frequency signal component of 
an electrical signal, such as an AMPWM signal, may be made 
based on empirical findings of frequencies that are known to 
be relevant to stimulating the biochemicals, the frequencies 
being those potentially different than resonant frequencies 
associated with the biochemicals. For example, the frequen 
cies for the low frequency signal component of an electrical 
signal, such as an AMPWM signal, may be selected to modu 
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late diminished levels of the neurotransmitter serotonin, the 
diminished levels being common to Such conditions as 
depression and chronic pain, as determined by the aforemen 
tioned comparative analysis. In various examples of pub 
lished literature, production of serotonin has been shown to 
be increased by stimuli at a frequency of between about one 
and 60 hertz, more preferably at about 10 hertz. In accordance 
with the method taught herein, the low frequency component 
of an AMPWM signal may therefore be selected to be 
between about one and 60 hertz, more preferably about 10 
hertz, in an attempt to increase serotonin production. 
A number of methods are provided for deriving, setting and 
altering quantities or parameters such as the frequency, phase, 
pulse width duty cycle, and/or amplitude of electrical signals 
for stimulating tissues, such as an AMPWM signal, wherein 
information may be transmitted between an electrical stimu 
lation apparatus as taught herein and a remote location. 
According to one Such method, measures of electrical 
parameters used to quantify the condition of tissues or any 
other appropriate functional State of a Subject may first be 
obtained as described above. Such electrical parameters may 
include, but are not limited to, tissue impedance, temperature, 
oxygen saturation, EEG activity, EMG activity, electrocar 
diographic activity, biochemical levels, and/or measures 
involving respiration patterns. These measures may be trans 
mitted to a remote location, via a network, such as the Internet 
or via another communication medium. 
As shown in FIG. 25, analysis and comparisons, similar to 
those described above, may be performed at the remote loca 
tion for the purpose of determining quantities such as the 
frequency, phase, pulse width duty cycle, amplitude, start 
time, and stop time parameters of electrical signals for stimu 
lating tissues, such as an AMPWM signal. The parameters for 
an electrical signal for stimulating tissues may then be trans 
mitted from the remote location, via a network, Such as the 
Internet or via other communication medium, to an electrical 
stimulation apparatus as taught herein, and used in the thera 
peutic application of the electrical signal on a Subject. In other 
words, a method is provided for electrically stimulating tissue 
that may include the determination of parametric values of an 
electrical tissue stimulation signal by taking measures of 
electrical properties of a Subject, then transmitting the mea 
Sures to a remote location via a network Such as the Internet, 
analyzing the measures at the remote location by, for 
example, making statistical comparisons between the mea 
Sures and measures known to represent normal tissue electri 
cal properties in a healthy normal population of living beings, 
remotely determining parametric values of an electrical tissue 
stimulation signal in response to the analysis, transmitting the 
parametric values from the remote location via a network 
Such as the Internet to an electrical stimulation apparatus, and 
causing the electrical stimulation apparatus to generate and 
apply to a region of the Subjects tissue an electrical stimula 
tion signal, e.g., a signal. Such as an AMPWM signal, con 
figured to reduce tissue impedance and increase depth of 
signal penetration, and having the remotely determined para 
metric values. 
Alternatively, according to this method, measures of elec 
trical parameters that are used to quantify the condition of 
tissues or other appropriate functional state of a Subject may 
be acquired during the therapeutic activity at a time generally 
concurrent to the application of the stimulation signal. Such 
electrical parameters may include, but are not limited to, 
tissue impedance, temperature, oxygen Saturation, EEG 
activity, EMG activity, electrocardiographic activity, bio 
chemical levels, and/or measures involving respiration pat 
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terns. These measures may be transmitted to a remote loca 
tion, via a network, such as the Internet or via other 
communication medium. 
Analysis and comparisons as described herein may be per 
formed at the remote location for the purpose of altering 
quantities such as the frequency, phase, pulse width duty 
cycle, amplitude, start time, and/or stop time parameters of 
electrical signals for stimulating tissues, such as an AMPWM 
signal. The determined parameters for altering an electrical 
signal for stimulating tissues may be transmitted from a 
remote location, via a network, Such as the Internet or via 
other communication medium, to an electrical stimulation 
apparatus as taught herein, and used in the further therapeutic 
application of the altered electrical signal on a Subject. In 
other words, taking measures may include acquiring mea 
Sures of electrical parameters from a subject as a stimulation 
signal is being applied to the Subject, and remotely determin 
ing includes altering quantities such as the frequency, phase, 
pulse width duty cycle, amplitude, start time, and/or stop time 
parameters of electrical tissue stimulation signals in response 
to Such measures taken as a stimulation signal is being 
applied. 
The analysis and comparisons as taught herein may be 
performed at the remote location for the purpose of determin 
ing changes in the electrical parameters over time, in accor 
dance with the application of therapeutic activities. Parameter 
changes overtime may be transmitted from a remote location, 
via a network, Such as the Internet, or via other communica 
tion medium, to a subjector a person of sufficient competence 
Such as a physician, and used to provide an indication of 
changes in the electrical parameters over time, in accordance 
with the application of therapeutic activities. 
In addition, symptom data may be acquired from a subject 
and transmitted via a network, such as the Internet, or via 
another communication medium, from a subject or a person 
of Sufficient competence, such as a physician, to the remote 
location for the purpose of tracking changes in Symptoms 
associated with a condition of the Subject over time, in accor 
dance with the application of therapeutic activities. In other 
words, symptom data may be acquired from a subject, trans 
mitted to the remote location via a communication medium 
Such as the Internet, and recorded at the remote location. 
Changes in the Subject's symptoms may be tracked by repeat 
ing the acquiring, transmitting, and recording of data on the 
Subjects symptoms. This symptom data may be compared to 
measures of electrical parameters acquired, and transmitted 
to a remote location either (a) periodically during the thera 
peutic activity, or (b) at a time generally concurrent with the 
stimulation signal being applied, as taught herein. A compari 
Son of symptom data and changes in electrical parameters 
may be made and transmitted from a remote location, via a 
network, such as the Internet, or via other communication 
medium, to a subject or a person of Sufficient competence 
Such as a physician, and used for the purpose of providing 
indication of changes in the symptoms over time in accor 
dance with the application of therapeutic activities. 
In accordance with the methods taught hereinforproviding 
feedback and information about changes in electrical param 
eters and/or symptoms, such feedback may include, but is not 
limited to, methods involving statistics or graphical represen 
tations of Such changes, any method of visually illustrating 
the changes, and any method of audibly illustrating the 
changes. 
A number of methods are provided for treatment of various 
conditions using electrical signals for stimulating tissues, 
such as an AMPWM signal. 
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FIG. 26 shows an exemplary flow diagram of exemplary 
action in accordance with one such method. As shown in FIG. 
26, in step S1, biophysical activity such as but not limited to 
biopotential voltages such as EEG and EMG may be mea 
sured in a portion of the subject’s body that is to be treated. 
This portion of the body to be treated may include a portion of 
the subjects brain, the subjects entire brain, body tissue 
containing an injury, body tissue near a bone injury, body 
tissue near a muscle injury, body tissue involved in or near a 
painful condition, and/or body tissue near a nerve causing 
health issues for example. 
As shown in step S2, the measured biophysical activity 
may be compared to normal biophysical activity for that 
portion of the body. The analysis of biophysical activity may 
involve either biophysical values from individual sites or 
multiple sites. The analysis may include statistical analyses of 
biophysical Voltages, their frequency components, and/or 
their phase components. In addition, the statistical analysis 
may include measures of variance, correlation, and/or coher 
ence. This step, either alone or in connection with steps S3 
and S4, as described further below, may be performed either 
at the location in which the measurements are taken, or at a 
remote location to which the measurements have been trans 
mitted. 
As shown in step S3, the site to which electrical stimulation 
will be applied may be determined, based on, for example, 
regions where the measured biophysical levels differ from the 
normal, desired biophysical activity. The differences in the 
biophysical levels are quantified and treatment sites may 
include regions where the frequency or amplitude compo 
nents of the subject’s biophysical levels exhibit greater values 
than normal, lower values than normal, and/or values that 
fluctuate more than normal. The site to which the electrical 
signal is to be applied may include muscles, bones, tendons, 
ligaments, cartilage, fascia, dermis, and/or internal organs. 
As shown in step S4, electrical parameters including, but 
not limited to, the frequency, phase, pulse width duty cycle, 
and amplitude may be determined for the electrical signal to 
be applied to the Subject, based on, for example, the analysis 
performed in step S2, to attempt to bring the subjects bio 
physical values for the determined site to more normal, 
desired values. 
As shown in step S5, at least one stimulating lead may be 
placed in proximity to the determined site. As shown in step 
S6, at least one ground lead may be placed so as to create a 
vector direction between the stimulating lead and the ground 
lead that passes through the site to be treated. In this manner, 
the path of the electrical stimulation will pass through the site 
to be treated. Any Suitable number of stimulation and ground 
leads may be used. 
As shown in step S7, an electrical signal may be applied 
through the leads, the electrical signal having the determined 
parameters such as, but not limited to, frequency, phase, pulse 
width duty cycle, and/or amplitude. The electrical signal may 
be, for example, an AMPWM signal, general examples of 
which are shown in FIGS. 7, 9, and 11, wherein the signal 
includes a high frequency signal component that is amplitude 
modulated by one or more low frequency components and 
further pulse width modulated. The high frequency signal 
component may be selected, for example, to overcome tissue 
impedance, and a low frequency signal component may pref 
erably be selected for its therapeutic effect. By using pulse 
width modulation for the purpose of varying the duty cycle of 
the electrical signal of relatively high frequency, the time 
averaged current deliverable by that signal can be controlled. 
Therefore, the pulse width duty cycle of the high frequency 
component may be selected, based on the analysis in S2, to 
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affect the time averaged current delivered by the AMPWM 
signal. The low frequency component of the electrical signal 
may be selected to modulate the excessive, diminished, and/ 
or variable biophysical activity at the determined site. The 
low frequency component of the AMPWM signal may 
include multiple frequency components. An AMPWM signal 
with multiple low frequency components is shown in FIG. 11. 
As shown in step S8, information may be acquired from a 
sensory input generally concurrent with the application of the 
electrical signal, to quantify the condition of either the site 
being treated with the electrical signal or the functional state 
of the Subject being treated. Such sensory inputs may include 
measures of biophysical activity, including but not limited to 
EEG, EMG, tissue impedance, temperature, oxygen satura 
tion, electrocardiographic activity, biochemical levels, and/or 
respiratory patterns. This monitoring of sensory inputs may 
occur as a continual process throughout the therapeutic appli 
cation of the electrical signal. Biophysical activity of the 
Subject may be sampled at times of minimal electrical stimu 
lation signal amplitude, Such as at Zero amplitude. 
As shown in Step S9, at least one characteristic parameter 
of the electrical signal may be altered based on a comparison 
of the information acquired from the sensory input and a 
desired value in a normal Subject. Electrical signal parameters 
Such as, but not limited to, the frequency, phase, pulse width 
duty cycle, and/or amplitude of the electrical signal may be 
altered. The application of the electrical signal may be 
stopped based on certain measures in tissue electrical prop 
erties being achieved. In addition, the particular leads used to 
apply the electrical stimulation may be varied. The compari 
son/analysis of the information acquired in step S8 may occur 
at the location at which the measurements are taken or at a 
remote location to which the sensory input information has 
been transmitted. 
A central nervous system condition of a Subject may be 
treated by Stimulating tissues in close proximity to the vagus 
nerve using an AMPWM signal. In one arrangement of lead 
placement, an electrode 122 of any stimulating lead 121 may 
be adapted to be placed at the posterior base of the neck of the 
subject near the first, second, or third cervical vertebrae. An 
electrode 122 of a ground lead 20 may be adapted to be placed 
on tissue in a position creating a vector between electrodes 
122 that passes near the vagus nerve. 
Abrain of a subject may be treated by stimulating tissues in 
close proximity to the vagus nerve using an AMPWM signal. 
In one arrangement of lead placement, an electrode 122 of any 
stimulating lead 121 may be adapted to be placed at the 
posterior base of the neck of the subject near the first, second, 
or third cervical vertebrae. An electrode 122 of a ground lead 
20 is adapted to be further placed on tissue, creating a vector 
between electrodes 122 that passes near the vagus nerve. 
Alternatively, a brain of a subject may be treated using an 
AMPWM signal. In one arrangement of lead placement, an 
electrode 122 of any stimulating lead 121 may be adapted to 
be placed on tissue of the subject near an area of the brain 
identified as having a dysfunction, such as, but not limited to, 
identification by EEG analysis. An electrode 122 of a ground 
lead 20 may be adapted to be further placed on tissue near the 
area of the brain identified as having a dysfunction, creating a 
vector between electrodes 122 that passes through the area of 
the brain identified as having the dysfunction. 
Tissues containing an injury may also be treated using an 
electrical tissue stimulation signal that reduces tissue imped 
ance and increases depth of signal penetration, such as an 
AMPWM signal. In one arrangement of lead placement, an 
electrode 122 of any stimulating lead 121 may be adapted to 
be placed on tissue of the subject near the location of the 
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injury. An electrode 122 of a ground lead 20 may be adapted 
to be further placed on tissue near the location of the injury, 
creating a vector between electrodes 122 that passes through 
the injury. 
Tissues containing an injury involving a bone may also be 
treated using a signal. Such as an AMPWM signal, configured 
to reduce tissue impedance and increase signal penetration 
depth. In one arrangement of lead placement, an electrode 
122 of any stimulating lead 121 may be adapted to be placed 
on tissue of a subject near the bone injury. An electrode 122 of 
a ground lead 20 may be adapted to be further placed on tissue 
near the bone injury, creating a vector between electrodes 122 
that passes through the bone injury. 
Tissues containing an injury involving a muscle may also 
be treated using a signal. Such as an AMPWM signal, config 
ured to reduce tissue impedance and increase signal penetra 
tion depth. In one arrangement of lead placement, an elec 
trode 122 of any stimulating lead 121 may be adapted to be 
placed on tissue of the Subject near the muscle injury. An 
electrode 122 of a ground lead 20 may be adapted to be further 
placed on tissue near a muscle injury, creating a vector 
between electrodes 122 that passes through the muscle injury. 
Muscle tissues containing a painful condition for a Subject, 
Such as a myofascial trigger point, may also be treated using 
a signal. Such as an AMPWM signal, configured to reduce 
tissue impedance and increase signal penetration depth. In 
one arrangement of lead placement, an electrode 122 of any 
stimulating lead 121 may be adapted to be placed on tissue of 
the Subject near the muscle containing a painful condition, 
Such as a myofascial trigger point. An electrode 122 of a 
ground lead 20 may be adapted to be further placed on tissue 
near the muscle containing a painful condition, creating a 
vector between electrodes 122 that passes through the muscle 
containing a painful condition; i.e., through the myofascial 
trigger point. 
A myofascial trigger point may also be treated using a 
signal, such as an AMPWM signal, configured to reduce 
tissue impedance and increase signal penetration depth. In 
one arrangement of lead placement, an electrode 122 of any 
stimulating lead 121 may be adapted to be placed on tissue of 
a subject near a myofascial trigger point. An electrode 122 of 
a ground lead 20 may be adapted to be further placed on tissue 
near a myofascial trigger point, creating a vector between 
electrodes 122 that passes through the myofascial trigger 
point. 
Myofascial pain may also be treated using an electrical 
tissue stimulation signal that reduces tissue impedance and 
increases depth of signal penetration, such as an AMPWM 
signal. In one arrangement of lead placement, an electrode 
122 of any stimulating lead 121 may be adapted to be placed 
on tissue of a subject near the location of myofascial pain. An 
electrode 122 of a ground lead 20 may be adapted to be further 
placed on tissue near the location of myofascial pain, creating 
a vector between electrodes 122 that passes through the tissue 
involved in myofascial pain. 
Conditions associated with central nervous system dys 
function may be treated with an electrical tissue stimulation 
signal that reduces tissue impedance and increases depth of 
signal penetration, such as an AMPWM signal. Such condi 
tions may include but are not limited to fibromyalgia Syn 
drome, chronic pain, traumatic brain injury, affective disor 
ders, such as attention deficit disorder (ADD) and attention 
deficit hyperactivity disorder (ADHD), chronic fatigue, sleep 
disorders, obsessive compulsive disorder, Tourette Syn 
drome, depression, anxiety, and addiction. 
Conditions associated with abnormal levels of biochemi 
cals including, but not limited to neurotransmitters and/or 
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neurochemicals in tissues, may be treated with an electrical 
signal for tissue stimulation that reduces tissue impedance 
and increases depth of signal penetration, Such as an 
AMPWM signal. Such conditions may include, but are not 
limited to, fibromyalgia syndrome, chronic fatigue, obesity, 
chronic pain, muscle pain, myofascial pain, myofascial trig 
ger points, and psychological conditions. Such as depression. 
Conditions may be treated by using an electrical tissue 
stimulation signal that reduces tissue impedance and 
increases depth of signal penetration, such as an AMPWM 
signal, to enhance a body's own healing mechanisms. Such 
conditions may include, but are not limited to, broken bones, 
injured tissues, post-Surgical wounds, cuts, muscle pain asso 
ciated with strains, and spasms. 
An electrical signal that reduces tissue impedance and 
increases depth of signal penetration, such as such as an 
AMPWM signal, may also be used for tissue stimulation for 
purposes of reducing fatigue, increasing alertness, or increas 
ing mental clarity. In other words, a method for improving a 
body's function is provided that includes applying an electri 
cal tissue stimulation signal to a Subject, where the signal is 
configured and applied in Such a way as to produce one or 
more beneficial effects Such as reducing fatigue, increasing 
alertness, and increasing mental clarity. 
An electrical tissue stimulation signal, e.g., a signal. Such 
as an AMPWM signal, that reduces tissue impedance and 
increases depth of signal penetration, may also be used for 
tissue stimulation for purposes of enhancing performance 
measures associated with, but not limited to, sporting activi 
ties, academic activities, and similar competitive endeavors. 
An electrical signal, such as an AMPWM signal, that 
reduces tissue impedance and increases depth of signal pen 
etration, may also be used for tissue stimulation for purposes 
of advantageously enhancing the function of organs. In one 
illustrative method, an AMPWM signal may be used to stimu 
late pancreatic tissues so as to enhance production of insulin, 
thereby affecting conditions such as diabetes. 
For various methods and apparatus taught herein, treat 
ment times may range between about 1 second and about 60 
minutes, with low frequency components of an AMPWM 
signal ranging between about 1 hertz and about 200 hertz, and 
high frequency components of an AMPWM signal ranging 
between about 100 hertz and about 1,000,000 hertz. The duty 
cycle of an AMPWM signal may range between about 1 
percent and about 99 percent, and assessment periods used for 
the purpose of analyzing acquired biopotential Voltages and 
selectively switching the use of leads may range between 
about 1 second and about 60 seconds. 
The following references are incorporated by reference in 
their entirety: 
1. “High-frequency stimulation of the subthalamic nucleus 
silences Subthalamic neurons: a possible cellular mechanism 
in Parkinson's Disease'. Magarinos-Ascone C, Pazo J. H 
Macadar O and Buno W. (Neuroscience 2002: 115(4): 1109 
17. 
2. “The spatial receptive field of thalamic inputs to single 
cortical simple cells revealed by the interaction of visual and 
electrical stimulation', Kara, Pezaris J. S. Yurgenson S and 
Reid, R. C. Proc Natl Acad Sci USA 2002 Dec. 10; 99(25): 
16261-6. 
3. "The anticonvulsant effect of electrical fields'. Wein 
stein S, Curr Neurol Neurosci Rep 2001 March; 1(2):155-61. 
4. "Electrical stimulation of the motor cortex in neuro 
pathic pain, Tronnier V. Schmerz 2001 August; 15(4):278-9. 
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5. "Centromedian-thalamic and hippocampal electrical 
stimulation for the control of intractable epileptic seizures'. 
Velasco M, Velasco F, Velasco AL. J. Clin Neurophysiol 2001 
November; 18(6):495-513 
The invention is not limited in any way to the embodiments 
described herein. In this regard, no attempt is made to show 
structural details of the invention in more detail than is nec 
essary for a fundamental understanding of the method of the 
invention. The description is intended only to make apparent 
to those skilled in the art how the several forms of the inven 
tion may be embodied in practice. 
I claim: 
1. A tissue stimulation apparatus comprising an electrical 
stimulation device that includes a stimulation signal genera 
tion circuit configured to generate an electrical tissue stimu 
lation signal comprising a therapeutic signal component and 
a penetration signal component wherein the penetration sig 
nal component is configured to reduce tissue impedance and 
increase depth of Stimulation signal penetration. 
2. A tissue stimulation apparatus as set forth in claim 1 in 
which the stimulation signal generation circuit is configured 
to generate an amplitude modulated pulse width modulated 
(AMPWM) signal. 
3. A tissue stimulation apparatus as set forth in claim 1 in 
which the stimulation signal generation circuit comprises a 
processor configured to control generation of electrical sig 
nals by the electrical stimulation device for tissue stimulation. 
4. A tissue stimulation apparatus as set forth in claim 3 in 
which the tissue stimulation apparatus includes an external 
computing device electrically coupled to the processor and 
configured to provide a user interface. 
5. A tissue stimulation apparatus as set forth in claim 4 in 
which the external computing device is configured to 
exchange data and control signals with the processor. 
6. A tissue stimulation apparatus as set forth in claim 4 in 
which the external computing device is configured to allow a 
user to modify operational parameters of the electrical stimu 
lation device. 
7. A tissue stimulation apparatus as set forth in claim 4 in 
which the external computing device is configured to estab 
lish parameters of the electrical signals generated by the 
device. 
8. A tissue stimulation apparatus as set forth in claim 4 in 
which the external computing device is configured to func 
tionally interface with at least one other network computing 
device. 
9. A tissue stimulation apparatus as set forth in claim 8 in 
which the external computing device is configured to func 
tionally interface with at least one of the other network com 
puting devices via the Internet. 
10. A tissue stimulation apparatus as set forth in claim 9 in 
which the external computing device is configured to func 
tionally interface with at least one of the other network com 
puting devices to determine parametric values of an electrical 
tissue stimulation signal, and to receive Subsequent corre 
sponding control data from the other network computing 
device via the functional interfaces. 
11. A tissue stimulation apparatus as set forth in claim 3 in 
which the stimulation signal generation circuit further com 
prises a digital-to-analog (D/A) converter configured to 
receive signal parameters from the processor and to generate 
a corresponding analog Voltage representing an electrical sig 
nal for stimulating tissues. 
12. A tissue stimulation apparatus as set forth in claim 11 in 
which the stimulation signal generation circuit further com 
prises a signal conditioning and amplification circuit config 
ured to receive the analog voltage from the D/A converter and 
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to generate a generally equivalent signal having one or more 
advantageous enhancements selected from the group of 
enhancements consisting of increased Voltage amplitude, 
decreased signal-to-noise ratio, and increased current capa 
bility. 
13. A tissue stimulation apparatus as set forth in claim 12 in 
which the tissue stimulation apparatus includes a plurality of 
stimulation leads and one or more ground leads configured to 
conduct electrical energy between tissues and the electrical 
stimulation device. 
14. A tissue stimulation apparatus as set forth in claim 13 in 
which the stimulation signal generation circuit is configured 
to selectively control the delivery of stimulating electrical 
signals to tissues through one or more selected ones of the 
stimulation leads. 
15. A tissue stimulation apparatus as set forth in claim 14 in 
which the stimulation signal generation circuit further 
includes a stimulation Switching circuit electrically coupled 
to the processor, the processor and stimulation Switching 
circuit being configured to Switch signals from the signal 
conditioning and amplification circuit to independent electri 
cal conduction paths that are electrically coupled with the 
respective stimulation leads. 
16. A tissue stimulation apparatus as set forth in claim 15 in 
which the stimulation signal generation circuit further 
includes a first ground Switching circuit electrically coupled 
with the independent electrical conduction paths and with the 
processor, the processor and ground Switching circuit being 
configured to selectively Switch the independent conduction 
paths to at least one system ground point. 
17. A tissue stimulation apparatus as set forth in claim 1 in 
which the electrical stimulation device includes: 
a battery connected to other circuits of the apparatus and 
configured to provide electrical power to other circuits 
of the electrical stimulation device; 
a battery charger and Switching circuit electrically coupled 
to the battery; and 
a processor electrically coupled to the battery charger and 
Switching circuit, the processor being configured to 
command the battery charger and Switching circuit to 
decouple the device from an external power source when 
isolation is desired and to couple the external power 
source to the battery to charge the battery when isolation 
is not desired. 
18. A tissue stimulation apparatus as set forth in claim 17 in 
which the electrical stimulation device includes at least one 
auxiliary control I/O connector electrically coupled with an 
input-output (I/O) port of the processor, the processor and 
control I/O connector being configured to provide control 
signals between the processor and a peripheral device. 
19. A tissue stimulation apparatus as set forth in claim 13 in 
which the apparatus includes at least one lead test port elec 
trically coupled to the processor and configured to electrically 
couple a conduction interface of one of the leads to the pro 
cessor, the processor being configured to test the electrical 
conducting integrity of the lead whose conduction interface 
has been coupled via the lead test port to the processor. 
20. A tissue stimulation apparatus as set forth in claim 19 in 
which the processor is configured to output an electrical sig 
nal of known properties to the lead whose conduction inter 
face has been coupled via the lead test port to the processor, 
and to acquire and test the resulting electrical signal con 
ducted through that lead and returned to the processor 
through the lead test port. 
21. A tissue stimulation apparatus as set forth in claim 20 in 
which processor is configured to determine the electrical 
conducting integrity of the lead whose conduction interface 
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has been coupled via the lead test port to the processor, by 
comparing the electrical signal of known properties to the 
signal conducted through that lead. 
22. A tissue stimulation apparatus as set forth in claim 1 in 
which the tissue stimulation apparatus includes one or more 
external stimulation devices electrically coupleable to the 
electrical stimulation device. 
23. A tissue stimulation apparatus as set forth in claim 22 in 
which the one or more external stimulation devices include 
one or more devices selected from the group of devices con 
sisting of an optical device, an electromagnetic device, and 
electromechanical device, and an audio device. 
24. A tissue stimulation apparatus as set forth in claim 22 in 
which the one or more external stimulation devices include an 
optical device comprising eyeglasses adapted to carry illumi 
nating devices. 
25. A tissue stimulation apparatus as set forth in claim 22 in 
which the one or more external stimulation devices include an 
optical device comprising one or more displays for showing 
images. 
26. A tissue stimulation apparatus as set forth in claim 22 in 
which the one or more external stimulation devices include an 
audio device adapted to play music. 
27. A tissue stimulation apparatus as set forth in claim 1 in 
which the tissue stimulation apparatus includes data collec 
tion instruments configured to collect data on a subject during 
periods of therapy and electrically coupled to the electrical 
stimulation device. 
28. A tissue stimulation apparatus as set forth in claim 13 in 
which the tissue stimulation apparatus includes a biopotential 
acquisition device configured to measure biopotential Voltage 
of tissues to be stimulated. 
29. A tissue stimulation apparatus as set forth in claim 28 in 
which the biopotential acquisition device includes an ampli 
fier module comprising a biopotential amplifier. 
30. A tissue stimulation apparatus as set forth in claim 29 in 
which the biopotential acquisition device includes at least one 
biopotential acquisition lead and at least one ground lead. 
31. A tissue stimulation apparatus as set forth in claim 30 in 
which the biopotential amplifier module is electrically cou 
pleable to the electrical stimulation device through anyone or 
more connectors selected from the group of connectors con 
sisting of stimulation lead connectors, auxiliary power Supply 
connector, control I/O connectors, and auxiliary I/O connec 
tors of the electrical stimulation device. 
32. A tissue stimulation apparatus as set forth in claim 31 in 
which the biopotential acquisition device is configured to 
measure anyone or more biopotential Voltages selected from 
the group of biopotential Voltages consisting of electroen 
cephalographic (EEG) Voltage, electromyographic (EMG) 
Voltage, and electrocardiographic Voltage. 
33. A tissue stimulation apparatus as set forth in claim 30 in 
which the tissue stimulation apparatus is configured for the 
biopotential amplifier to measure biopotential Voltage of tis 
Sue as the electrical stimulation device provides stimulation 
to the tissue. 
34. A tissue stimulation apparatus as set forth in claim 33 in 
which the biopotential acquisition device includes at least one 
inductor electrically coupled to the electrical stimulation 
device and operatively coupleable to at least one biopotential 
acquisition lead, the electrical stimulation device and the at 
least one inductor being configured to deliver tissue stimula 
tion signals through the at least one biopotential acquisition 
lead. 
35. A tissue stimulation apparatus as set forth in claim 33 in 
which the biopotential acquisition device includes one or 
more inductors electrically coupled to the electrical stimula 
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tion device and operatively coupleable to one or more respec 
tive biopotential acquisition leads, the electrical stimulation 
device and inductors being configured to selectively deliver 
tissue stimulation signals through the one or more biopoten 
tial acquisition leads. 
36. A tissue stimulation apparatus as set forth in claim 33 in 
which the biopotential acquisition device includes at least one 
adjunct Switching circuit and an adjunct Switching control 
electrically coupled to the electrical stimulation device, the 
adjunct Switching circuit being operatively coupleable to at 
least one biopotential acquisition lead, the electrical stimula 
tion device and an adjunct Switching control being configured 
to selectively connect the electrical stimulation device to 
selected leads to transmit tissue stimulation signals to the 
selected leads and to connect selected leads to the biopoten 
tial amplifier to transmit biopotential voltages to the biopo 
tential amplifier. 
37. A tissue stimulation apparatus as set forth in claim 30 in 
which the electrical stimulation device is configured to use at 
least one biopotential acquisition lead for both acquiring bio 
potential Voltage and delivering an electrical tissue stimula 
tion signal. 
38. A tissue stimulation apparatus as set forth in claim 37 in 
which the electrical stimulation device is configured to use at 
least one biopotential acquisition lead for simultaneously 
acquiring biopotential Voltage and delivering an electrical 
tissue stimulation signal. 
39. A tissue stimulation apparatus as set forth in claim38 in 
which the electrical stimulation device is configured to selec 
tively sample biopotential voltage data from the biopotential 
acquisition device at times of minimal electrical stimulation 
signal amplitude. 
40. A tissue stimulation apparatus as set forth in claim 39 in 
which the electrical stimulation device is configured to selec 
tively sample biopotential voltage data from the biopotential 
acquisition device over assessment periods of between about 
I second and about 60 seconds. 
41. A tissue stimulation apparatus as set forth in claim 39 in 
which the electrical stimulation device is configured to selec 
tively sample biopotential voltage data from the biopotential 
acquisition device at times of minimal electrical stimulation 
signal amplitude within the period of a high frequency signal 
component of an AMPWM signal. 
42. A tissue stimulation apparatus as set forth in claim 1 in 
which the electrical stimulation device is configured to select 
the frequencies of a high frequency signal component of an 
AMPWM signal to be multiples of integral powers of two. 
43. A tissue stimulation apparatus as set forth in claim 42 in 
which the electrical stimulation device is configured to select 
the frequencies of a high frequency signal component of an 
AMPWM signal to be integral multiples of 256. 
44. A tissue stimulation apparatus as set forth in claim 42 in 
which the electrical stimulation device is configured to math 
ematically analyze acquired biopotential Voltage data using a 
Fourier Transform analysis whereupon a number of Samples 
per second is equal to an integral power of two. 
45. A tissue stimulation apparatus as set forth in claim 30 in 
which the tissue stimulation apparatus is configured to use 
biopotential Voltage data to determine parametric values of an 
electrical tissue stimulation signal. 
46. A tissue stimulation apparatus as set forth in claim 45 in 
which an external computing device is configured to deter 
mine parametric value of an electrical tissue stimulation sig 
nal in response to biopotential Voltage data obtained by the 
biopotential acquisition device and to send corresponding 
control data to the processor. 
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47. A tissue stimulation apparatus as set forth in claim 46 in 
which the biopotential acquisition device is an EEG acquisi 
tion device and the external computing device is configured to 
determine parametric value of an electrical tissue stimulation 
signal in response to EEG data obtained by the EEG acqui 
sition device and to send corresponding control data to the 
processor. 
48. A tissue stimulation apparatus as set forth in claim 46 in 
which the tissue stimulation apparatus is configured to use at 
least one biopotential acquisition lead as either a conduction 
path for an electrical tissue stimulation signal, a conduction 
path for carrying a biopotential Voltage to the biopotential 
amplifier, or a ground. 
49. A tissue stimulation apparatus as set forth in claim 48 in 
which the processor is configured to selectively switch a 
biopotential acquisition lead to an apparatus ground point by 
sending corresponding control signals to the second ground 
Switching circuit. 
50. A tissue stimulation apparatus as set forth in claim 46 in 
which the processor is configured to differentially compare 
biopotential Voltages at more than one acquisition site on a 
tissue by selectively using biopotential acquisition leads as 
reference leads to the biopotential amplifier or as differential 
leads to the biopotential amplifier. 
51. A tissue stimulation apparatus as set forth in claim 1 in 
which the tissue stimulation apparatus includes an impedance 
testing circuit configured to monitor the impedance of tissues, 
the apparatus being configured to determine parametric val 
ues of an electrical tissue stimulation signal in response to 
tissue impedance data acquired by the impedance testing 
circuit. 
52. A tissue stimulation apparatus as set forth in claim 51 in 
which the impedance testing circuit is coupled to the electri 
cal stimulation device and a biopotential amplifier of a bio 
potential acquisition device and is configured to monitor the 
impedance of tissues in contact with at least one ground lead 
and at least one biopotential acquisition lead of the biopoten 
tial acquisition device and to transfer Such data to the proces 
SO. 
53. A tissue stimulation apparatus as set forth in claim 51 
further including an external computing device coupled to the 
processor and configured to analyze tissue impedance data 
and to send corresponding control data to the processor for 
altering parametric parameters of electrical tissue stimulation 
signals. 
54. A tissue stimulation apparatus as set forth in claim 1 in 
which the tissue stimulation apparatus includes an impedance 
testing circuit that is coupled with the biopotential amplifier 
ofa biopotential acquisition device and is configured to moni 
tor biopotential Voltage integrity. 
55. A tissue stimulation apparatus as set forth in claim 54 in 
which the tissue stimulation apparatus is configured to indi 
cate to a user when good biopotential Voltage integrity is 
achieved. 
56. A tissue stimulation apparatus as set forth in claim 54 in 
which the tissue stimulation apparatus is configured to gen 
erate an alert when biopotential Voltage integrity is lost. 
57. A tissue stimulation apparatus as set forth in claim 1 in 
which the tissue stimulation apparatus comprises: 
a Sensor Set, 
an independent biopotential Voltage measurement appara 
tus; and 
an adjunct electrical stimulation apparatus operatively 
connected between the sensor set and the independent 
biopotential Voltage measurement apparatus, opera 
tively coupled to the electrical stimulation device, and 
configured to transmit to the sensor set electrical tissue 
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stimulation signals received from the electrical stimula 
tion device, to transmit biopotential Voltage from the 
sensor set to the independent biopotential Voltage mea 
Surement apparatus, and to receive control signals from 
a processor of the electrical stimulation device. 
58. A tissue stimulation apparatus as set forth in claim 57 in 
which the biopotential measurement apparatus is an EEG 
measurement apparatus and the sensor set is an EEG sensor 
Set. 
59. A tissue stimulation apparatus as set forth in claim 57 in 
which the sensorset comprises at least one electrode and a cap 
configured to position the at least one electrode and to be 
worn by a Subject. 
60. A tissue stimulation apparatus as set forth in claim 57 in 
which in which the adjunct electrical stimulation apparatus 
includes: 
an adjunct Switching control operatively coupled to the 
processor of the electrical stimulation device; 
a plurality of adjunct Switching circuits operatively 
coupled to the adjunct Switching control, to the electrical 
stimulation device, to the independent biopotential mea 
Surement apparatus, and to respective electrodes of the 
sensorset; and 
the processor and adjunct Switching control are configured 
to provide selectable conduction pathways for tissue 
stimulation signals between the electrical stimulation 
device and the electrodes of the sensorset, and for bio 
potential voltages between the electrodes of the sensor 
set and the biopotential Voltage measurement apparatus. 
61. A tissue stimulation apparatus as set forth in claim 60 in 
which in which the processor and adjunct Switching circuits 
are configured to provide selectable conduction pathways 
between the electrodes of the sensor set and a ground. 
62. A tissue stimulation apparatus as set forth in claim 57 in 
which the adjunct electrical stimulation apparatus includes: 
a ground Switching circuit operatively coupled to the pro 
cessor of the electrical stimulation device, to the biopo 
tential amplifier, and by conduction paths to respective 
electrodes of the sensorset: 
a plurality of inductors operatively coupled to the electrical 
stimulation device and to the conduction paths; and 
the processor and ground Switching circuit are configured 
to provide selectable conduction pathways for tissue 
stimulation signals between the electrical stimulation 
device and the electrodes of the sensorset, and for bio 
potential voltages between the electrodes of the sensor 
set and the biopotential Voltage measurement apparatus. 
63. A tissue stimulation apparatus as set forth in claim 62 in 
which the processor and ground Switching circuit are config 
ured to provide selectable conduction pathways between the 
electrodes of the sensor set and a ground. 
64. A tissue stimulation apparatus as set forth in claim 60 in 
which the adjunct electrical stimulation apparatus includes at 
least one Switching control conductor electrically coupled to 
an adjunct Switching circuit and configured to determine the 
state of the adjunct Switching circuit and a conduction path 
provided to a corresponding electrode of the sensorset. 
65. A tissue stimulation apparatus as set forth in claim 57 in 
which the processor of the electrical stimulation device and 
the adjunct Switching control are configured to: 
direct biopotential voltage from selected electrodes of the 
sensorset to the biopotential measurement apparatus by 
Selective Switching via the adjunct Switching control 
operated by the processor when a biopotential Voltage 
measurement is required; 
to direct a tissue stimulation signal from the electrical 
stimulation device to selected electrodes of the sensor 
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set by selective Switching via the adjunct Switching con 
trol operated by the processor when tissue stimulation is 
required; and 
to couple an electrode of the sensor set to ground by selec 
tive Switching via the adjunct Switching control operated 
by the processor when grounding of an electrode is 
desired. 
66. A tissue stimulation apparatus as set forth in claim 1 
and further comprising: 
a mobile apparatus carrying the electrical stimulation 
device; and 
a material Supplies storage and use apparatus carried by the 
mobile apparatus and configured to carry consumable 
Supplies for use in administering tissue stimulation sig 
nals to a Subject. 
67. A tissue stimulation apparatus as set forth in claim 66 in 
which the material Supplies storage and use apparatus is con 
figured to carry any number of consumable Supplies selected 
from the group of Supplies consisting of conductive pastes, 
conductive gels, cleaning materials, cleaning agents, and Sup 
porting materials. 
68. A tissue stimulation apparatus as set forth in claim 66 in 
which the material Supplies storage and use apparatus com 
prises a plurality of receptacles configured to store any num 
ber of items selected from the group of items consisting of a 
waste, conductive gel, conductive paste, cleaning materials, 
alcohol, Supporting materials, and electrodes. 
69. A tissue stimulation apparatus as set forth in claim 66 in 
which the material supplies storage and use apparatus 
includes an electrode storage receptacle configured to store 
and block light from reaching lead electrodes comprising 
photosensitive materials. 
70. A tissue stimulation apparatus as set forth in claim 66 in 
which the tissue stimulation apparatus includes one or more 
sensors carried by the material Supplies and use apparatus and 
configured to sense the quantities of materials stored in recep 
tacles of the material Supplies storage and use apparatus. 
71. A tissue stimulation apparatus as set forth in claim 66 in 
which the tissue stimulation apparatus includes an external 
computing device coupled to the one or more sensors and 
configured to manage inventory in response to signals 
acquired from the one or more sensors. 
72. A tissue stimulation apparatus as set forth in claim 71 in 
which the tissue stimulation apparatus is configured to gen 
erate an alert when inventory of any material reaches a pre 
determined low point. 
73. A tissue stimulation apparatus as set forth in claim 71 in 
which the tissue stimulation apparatus is configured to order 
materials necessary to replenish inventory when a predeter 
mined low point is reached. 
74. A tissue stimulation apparatus as set forth in claim 71 in 
which the tissue stimulation apparatus is configured to order 
materials by interfacing with a communications network. 
75. A tissue stimulation apparatus as set forth in claim 66 in 
which the electrical stimulation apparatus is configured to 
provide stimulation through composite stimulation leads, the 
composite stimulation leads comprising a combination of 
stimulation leads and ground leads. 
76. A tissue stimulation apparatus as set forth in claim 75 in 
which the composite stimulation leads include external 
stimulation device cables. 
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